UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): September 12, 2013

 

 

COLUMBIA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-10352   59-2758596

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

4 Liberty Square

Fourth Floor

Boston, Massachusetts

  02109
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 639-1500

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 1.01. Entry into a Material Definitive Agreement.

On September 12, 2013, Columbia Laboratories, Inc. (the “Company”), through its subsidiary Columbia Laboratories UK, Limited (“CBRX UK” and together with the Company, “Columbia”) acquired 100% of the share capital of Molecular Profiles Limited, an English private limited company (“Molecular Profiles”), pursuant to a Share Purchase Agreement (the “Purchase Agreement”) among Columbia and the sellers listed on Schedule 1 thereto (the “Sellers”). Molecular Profiles is engaged in the business of pharmaceutical development and manufacturing services in the United Kingdom.

The total value of the acquisition consideration was approximately $25 million, comprising $16.7 million in cash (equivalent to approximately £10.6 million) and the Company issued 1,051,323 shares of its common stock (equivalent to approximately $8.3 million), based on the average closing price of the Company’s common stock on the NASDAQ Capital Market for the twenty trading days immediately preceding the date of the Purchase Agreement. The newly issued shares are subject to a twelve-month lock-up period. The total consideration paid excludes transaction costs and is subject to a potential downwards only post-closing adjustment. $2 million (equivalent to approximately £1.27 million) of the cash portion of the consideration has been deposited in escrow as a source of funding for any such adjustment.

Pursuant to the Purchase Agreement, the Company agreed to appoint Dr. Nikin Patel, the Chief Executive Officer of Molecular Profiles to the Company’s Board of Directors. The Parties to the Purchase Agreement have made customary representations, warranties and covenants therein. The assertions embodied in those representations and warranties were made for purposes of the Purchase Agreement and are subject to qualifications and limitations agreed by the respective parties in connection with negotiating the terms of the Purchase Agreement. In addition, certain representations and warranties made as of a specified date may be subject to a contractual standard of materiality different from what might be viewed as material to stockholders, or may have been used for the purpose of allocating risk between the respective parties rather than establishing matters as facts. For the foregoing reasons, no person should rely on the representations and warranties as statements of factual information at the time they were made or otherwise.

The foregoing summary of the acquisition and the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement attached hereto as Exhibit 2.1 and is incorporated by reference.

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On September 5, 2013, Molecular Profiles entered into a grant letter (the “Grant Letter”) with the Secretary of State for Business, Innovation and Skills. Pursuant to the Grant Letter, the Secretary of State for Business, Innovation and Skills agreed to grant Molecular Profiles up to £1,600,000 (the “Grant”) under Section 8 of the Industrial Development Act 1982 in the furtherance of the implementation by Molecular Profiles of a project to expand a current facility by building additional space for a manufacturing facility, analytical labs and office space, as well as the creation of a specified number of jobs. The Grant is conditional upon the completion and reporting of certain project milestones as specified in the Grant Letter and the execution by the Company of a parent guarantee (the “Parent Guarantee”), dated September 12,


2013, whereby the Company has agreed to guarantee all obligations of Molecular Profiles under the Grant Letter including all monies, debts and liabilities (whether actual or contingent) from time to time due, owning or incurred by or from Molecular Profiles to the Secretary of State under or in connection with the Grant Letter (the “Guaranteed Obligations”). The Grant Letter provides that the Grant may become repayable under certain specified circumstances within a six (6) year monitoring period, as defined in the Grant Letter, including, but not limited to, failure to progress to reach specified targets on the project, significant changes to the nature and scale of the project or financing of the project, the future of the project being in jeopardy, events occurring that would have a material adverse effect on the ability of the Company to perform its obligations under the guarantee and failure to comply with conditions specified in the Grant Letter and the schedules included therein. Under the terms of the Parent Guarantee, the Company is required to pay on demand any of the Guaranteed Obligations when due, as the guarantor or surety of Molecular Profiles. Where payments cannot be recovered from the Company as guarantor or surety of Molecular Profiles sums can also be recovered from the Company as a principal debtor. Any amounts due from the Company carry interest of 1.5% above the base rate of the Bank of England or at the European Commission’s reference rate for the United Kingdom as published in the Official Journal from time to time, whichever is higher, from the date of demand to the date of payment.

The foregoing summary of the Parent Guarantee does not purport to be complete and is qualified in its entirety by reference to the Parent Guarantee attached hereto as Exhibit 10.1 and is incorporated by reference.

 

Items 3.02. Unregistered Sales of Equity Securities.

As described in Item 1.01 above (the applicable portions of which are incorporated by reference into this Item 3.02), approximately $8.3 million of the aggregate purchase price paid in connection with the acquisition consisted of 1,051,323 shares of Company common stock, which were issued to the Sellers pursuant to the terms of the Purchase Agreement. The newly issued shares are subject to a twelve-month lock-up period and were issued in transactions exempt from registration under the Securities act of 1933, as amended, in reliance on exemptions provided by Regulation S and/or Regulation D.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 10, 2013, the board of directors (the “Board”) of the Company voted to increase the size of the Board from six to eight members and to appoint Dr. Nikin Patel and Dr. Frank Armstrong as new directors to fill the vacancies created by such increase, contingent upon the closing of the acquisition.

Pursuant to the Purchase Agreement, the appointment of Dr. Patel was effective upon the closing of the transactions contemplated by the Purchase Agreement. Dr. Patel will serve as CEO, Molecular Profiles and Director of the Company. The terms of Dr. Patel’s employment are governed by the terms of the employment agreement, dated September 12, 2013, attached hereto as Exhibit 10.2.

Dr. Patel is the founding Chief Executive Officer of Molecular Profiles. Dr. Patel has over 15 years’ technical experience centered on pharmaceutical analysis and formulation development. His leadership was recognized externally through the U.K.’s most prestigious industry accolade, the Queen’s Award for Enterprise, won by Molecular Profiles both in 2007 and 2011 in the Innovation category.

Dr. Patel holds a first class honors degree and Ph.D. in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS). In addition to Columbia Laboratories, he is currently a director of Regentec Ltd, a regenerative medicine company.


Dr. Armstrong was appointed to the Board to serve as an independent director, effective upon the closing of the transaction contemplated by the Purchase Agreement. Dr. Armstrong was not selected pursuant to any arrangement or understanding with the Company or any affiliate of the Company. Dr. Armstrong has no relationship that is required to be disclosed pursuant to Item 404(a) of Regulation S-K. Dr. Armstrong’s compensation for his services as a director will be consistent with that of our other non-employee directors, including the execution of an indemnification agreement with Dr. Armstrong in the form previously approved by the Board.

Dr. Armstrong has over 20 years of experience in development and management at major pharmaceutical and leading biotechnology companies, spanning all aspects of the drug evaluation, development and commercialization processes. Dr. Armstrong led Medical Science and Innovation in R&D at Merck Serono and previously led Worldwide Product Development at Bayer AG and the Worldwide Medical Organization at Zeneca. He also served as CEO of Fulcrum Pharma plc and President and CEO of CuraGen Corp., among others.

Dr. Armstrong holds an honors degree and MBChB (awarded as an MD in the United States) in Biochemistry and Medicine from the University of Edinburgh in Scotland. He was elected as a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) in 1994, and Fellow of Royal College of Physicians, Edinburgh (FRCPE) in 1993. He currently serves on the Boards of six healthcare companies: Summit plc (non-executive Chairman), Asceneuron SA (executive Chairman), Xceleron (Chairman), Actino Pharma, Entelos and CardioRentis (non-executive Director).

In addition to the appointments to the Board of Drs. Patel and Armstrong, the Board approved the appointment of Dr. Martyn Davies to the position of Board Advisor.

Dr. Davies has over 30 years’ experience in the pharmaceutical, biopharmaceutical and drug delivery fields. He co-founded Molecular Profiles in 1997 as a spin-out company from his academic laboratory, and served as the company’s Founder-Chairman until its acquisition by Columbia Laboratories in September 2013. He played a key role in Molecular Profiles’ strategic development and also in leading and consulting on many technical projects for clients. Dr. Davies is also a Professor at the University of Nottingham’s School of Pharmacy.

Dr. Davies holds a first class honors degree in Pharmacy from Brighton Polytechnic and a Ph.D. from King’s College, University of London. He has authored or co-authored more than 370 articles, is a Fellow of the Royal Society for Chemistry (FRSC) and Royal Pharmaceutical Society of Great Britain (FRPharmS), and is a past President of the Controlled Release Society (2011-12).

 

Item 7.01. Regulation FD Disclosure.

On September 12, 2013, the Company issued a press release announcing the closing of the Company’s acquisition of Molecular Profiles. A copy of the press release was furnished as Exhibit 99.1 to the Current Report on Form 8-K filed on September 12, 2013. On September 16, 2013, the Company issued a press release entitled “Columbia Laboratories Expands its Board of Directors” announcing the appointment to the Board of Drs. Nikin Patel and Frank Armstrong and the appointment of Dr. Martyn Davies to the position of Board Advisor.

A copy of the press release is furnished and attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Without limiting the generality of the foregoing, the “Forward-Looking Statements” disclosure contained in the press release is incorporated by reference into this Item 7.01. The information contained


in this Item 7.01 and the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.

 

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired

The financial statements required by this Item 9.01(a) are currently being prepared. The Company will file the required financial statements under the cover of Form 8-K/A as soon as practicable but not later than 71 calendar days after the latest date on which this initial Current Report on Form 8-K is required to be filed.

(b) Pro forma Financial Information

The financial statements required by this Item 9.01(b) are currently being prepared. The Company will file the required financial statements under the cover of Form 8-K/A as soon as practicable but not later than 71 calendar days after the latest date on which this initial Current Report on Form 8-K is required to be filed.

 

(d) Exhibits .

 

Exhibit
No.

  

Description

  2.1    Share Purchase Agreement between the sellers listed on schedule 1 thereto, and Columbia Laboratories, Inc. and Molecular Profiles Limited, dated September 12, 2013.
10.1    Parent Guarantee of Columbia Laboratories, Inc., dated September 12, 2013.
10.2    Employment Agreement between Dr. Nikin Patel and Columbia Laboratories, Inc., dated September 12, 2013.
99.1    Press Release dated September 16, 2013, entitled “Columbia Laboratories Expands Board of Directors.”


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

COLUMBIA LABORATORIES, INC.
  By:  

/s/ Jonathan Lloyd Jones

  Name:   Jonathan Lloyd Jones
  Title:   Vice President & Chief Financial Officer

Date: September 18, 2013

Exhibit 2.1

D ATED

September 2013

S HARE PURCHASE AGREEMENT

between

T HE S ELLERS

and

C OLUMBIA L ABORATORIES , I NC .

AND

M OLECULAR P ROFILES L IMITED


Contents

clause

 

1.  

Interpretation

     1   
2.  

Columbia Stock

     9   
3.  

share subscription moneys

     9   
4.  

Sale and purchase

     9   
5.  

Payment of Purchase price

     10   
6.  

Completion

     10   
7.  

Purchase Price Adjustment

     12   
8.  

Warranties

     12   
9.  

Limitations on claims

     13   
10.  

Escrowed Funds

     19   
11.  

Claims

     21   
12.  

gross up

     23   
13.  

Tax indemnity, Tax Compliance and Access to Information

     23   
14.  

Sellers’ Representative

     36   
15.  

Restrictions on the Covenantors

     37   
16.  

Termination of the Shareholders Agreement

     38   
17.  

Confidentiality and announcements

     39   
18.  

Further assurance

     39   
19.  

Assignment

     39   
20.  

Whole agreement

     40   
21.  

Variation and waiver

     40   
22.  

Costs

     41   
23.  

Notice

     41   
24.  

Severance

     42   
25.  

Agreement survives completion

     42   
26.  

Third party rights

     42   
27.  

Successors

     43   
28.  

Counterparts

     43   
29.  

Governing law and jurisdiction

     43   
Schedule   
S CHEDULE 1 P ARTICULARS OF THE S ELLERS AND THE S HARES      44   
S CHEDULE 2 P ARTICULARS OF THE C OMPANY      45   
S CHEDULE 3 C OMPLETION      46   
Part 1. What the Sellers shall deliver to the Buyer at Completion   
Part 2. Matters for the Board meeting at Completion   
S CHEDULE 4 W ARRANTIES      47   
1.  

Power to sell the company

  
2.  

Shares in the company

  
3.  

Information

  


4.  

Compliance with laws

  
5.  

Licences and consents

  
6.  

Insurance

  
7.  

Disputes and investigations

  
8.  

Competition

  
9.  

Contracts and Trading

  
10.  

Transactions with the Sellers

  
11.  

Finance and guarantees

  
12.  

Condition of equipment

  
13.  

Insolvency

  
14.  

Assets

  
15.  

Intellectual property

  
16.  

Information technology

  
17.  

Data protection

  
18.  

Employment

  
19.  

Environmental

  
20.  

Property

  
21.  

Accounts and Management Accounts

  
22.  

Accounting, financial and other records

  
23.  

Changes since accounts date

  
24.  

Retirement benefits

  
25.  

Tax

  
26.  

Transaction Expenses

  
S CHEDULE 5 P ARTICULARS OF PROPERTIES      48   
Part 1. Freehold properties   
Part 2. Leasehold properties   
S CHEDULE 6     C OMPLETION A CCOUNTS      49   
S CHEDULE 7     F URTHER P ROVISIONS RE C OLUMBIA S TOCK      50   
S CHEDULE 8     I NTELLECTUAL P ROPERTY      51   
S CHEDULE 9     L IST OF M ATERIAL C ONTRACTS      52   
S CHEDULE 10   O PTION E XERCISE N OTICE      53   


THIS AGREEMENT is dated September 2013

P ARTIES

 

(1) Each person whose name appears in Schedule 1 (each a Seller ).

 

(2) Columbia Laboratories, Inc. a corporation incorporated in Delaware whose principal place of business is at 4 Liberty Square, Boston, MA 02109, USA ( Buyer ).

 

(3) Molecular Profiles Limited a company incorporated in England and Wales with company number 03397582 whose registered office is at 8 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX ( Company ).

B ACKGROUND

 

1. The Sellers own the entire issued and allotted share capital of the Company which the Sellers have agreed to sell, and the Buyer has agreed has to buy, subject to the terms of this Agreement.

 

2. The Company is a party to the Shareholders Agreement (as defined below) and is a party to this Agreement solely for the purposes of clause 16.

A GREED TERMS

 

1. I NTERPRETATION

 

1.1 The definitions and rules of interpretation in this clause apply in this Agreement.

 

1.2 Definitions

Accounts: the 2012 Accounts, the 2013 Accounts and the Management Accounts.

Accounts Date: each of 31 July 2012, 31 July 2013 and 31 August 2013.

Agreed Columbia Stock Price: subject to clause 2.3, US$7.895 per share of Columbia Stock being the 20-trading day average closing price for the 20 trading day period ended soonest before the date of this Agreement.

Annual Accounts: each of the 2012 Accounts and the 2013 Accounts.

Business Day: a day (other than a Saturday, Sunday or public holiday) when banks in the Cities of London and New York are open for business.

Buyer’s Solicitors: Reed Smith LLP of Broadgate Tower, 20 Primrose Street, London, United Kingdom, EC2A 2RS.

Buyer’s Solicitors’ Client Account: Account No: 40098523 at Barclays Bank Plc 1 Churchill Place London E14 5HP, Sort Code: 20-00-00 or such other bank account as shall be designated as the Buyer’s Solicitors’ Client Account by written notice to the Sellers’ Solicitors from the Buyer’s Solicitors.

 

1


Buyer’s Tax Group: the Buyer and any company which at the relevant time is treated as a member of the same group of companies as the Buyer or associated or connected with the Buyer, in each case for the purposes of any Tax or Relief pursuant to Tax Legislation .

CAA 2001: the Capital Allowances Act 2001.

Claim: a claim for breach of any of the Warranties or a claim under the Tax Indemnity.

Columbia Stock: subject to clause 2.3, the common stock, par value US$0.01 per share, of the Buyer.

Company Intellectual Property: all Intellectual Property Rights owned or controlled by the Company at the date of this Agreement including the registered Company Intellectual Property set out at Schedule 8 Part A, and all rights of the Company under the IP Licences and the IT Contracts.

Competition Law: the national and directly effective legislation of any jurisdiction which governs the conduct of companies or individuals in relation to restrictive or other anti-competitive agreements or practices (including, but not limited to, cartels, pricing, resale pricing, market sharing, bid rigging, terms of trading, purchase or supply and joint ventures), dominant or monopoly market positions (whether held individually or collectively) and the control of acquisitions or mergers.

Company’s Account: Account No: 43682868 at Lloyds TSB Bank Plc, Old Market Square, Nottingham, Sort Code: 30-96-18.

Completion: completion of the sale and purchase of the Shares in accordance with this Agreement.

Completion Accounts : means the accounts to be prepared in accordance with Schedule 6.

Completion Date: the date of this Agreement.

Connected: in relation to a person, has the meaning given in section 1122 of the Corporation Tax Act 2010 but without prejudice to the generality of this definition the following Seller shall be deemed to be Connected with the following entity:

 

Seller

  

Connected Entity

Martyn Christopher Davies    Chemical Profiles LLP

Consultancy Agreement: each consultancy agreement between the Company and Chemical Profiles LLP, Clive Jonathan Roberts or Philip Williams in the agreed form.

Covenantor : means each Seller except for the University of Nottingham.

Covenantor Proportion : each of the proportions set out in column 9 of the table at Schedule 1.

CTA 2009: Corporation Tax Act 2009.

 

2


CTA 2010: Corporation Tax Act 2010.

Director: each person who is a director or shadow director of the Company.

Disclosed: fairly disclosed (with sufficient details to identify the nature and scope of the matter disclosed) in or under the Disclosure Letter.

Disclosure Letter: the letter from the Warrantors to the Buyer with the same date as this Agreement and described as the disclosure letter, including the bundle of documents attached to it ( Disclosure Bundle ).

Employee: any person employed by the Company under a contract of employment.

Employment Legislation: legislation applying in England and Wales affecting contractual or other relations between employers and their employees or workers, including but not limited to any legislation and any amendment, extension or re-enactment of such legislation (to the extent in force immediately prior to Completion) and any claim arising under European treaty provisions or directives enforceable against the Company by any Employee or Worker.

Encumbrance: any interest or equity of any person (including any right to acquire, option or right of pre-emption) or any mortgage, charge, pledge, lien, assignment, hypothecation, security interest, title retention or any other security agreement or arrangement.

Environment: air, water and land, all living organisms and natural or man-made structures.

Environmental Law: any law in so far as it relates to Environmental Matters.

Environmental Matters: the protection of human health, the protection and condition of the Environment, the condition of the workplace, the generation, transportation, storage, treatment, emission, deposit and disposal of any Hazardous Substance or Waste.

Escrow Account: an account at Santander Bank to be opened in the joint names of the Escrow Agents.

Escrow Agents: the Buyer’s Solicitors and the Sellers’ Solicitors.

Escrow Agreement: the letter agreement of that name in the agreed form.

First Release Date : has the meaning ascribed to that term in clause 10.1.

Fully Paid Share: each Share in respect of which the full amount of the nominal value and any share premium has been received by the Company or has been validly credited as fully paid.

Group: in relation to a company, that company, its subsidiaries, subsidiary undertakings, any company of which it is a subsidiary (its holding company) or subsidiary undertaking (its parent undertaking); and each company in a group is a member of the group.

 

3


Unless the context otherwise requires, the application of the definition of Group to any company at any time will apply to the company as it is at that time.

Hazardous Substance: any natural or artificial substance (whether solid, liquid or gas and whether alone or in combination with any other substance or radiation), capable of causing harm to the Environment.

holding company and subsidiary: a “holding company” and “subsidiary” as defined in section 1159 of the Companies Act 2006.

Initial Consideration : the Initial Cash Consideration and the Stock Consideration.

Initial Cash Consideration: £10,623,452.76 to be satisfied by payment of the Initial Cash Consideration On-Account Payment and the Initial Cash Consideration Escrow Payment.

Initial Cash Consideration On-Account Payment : £9,351,188.13

Initial Cash Consideration Escrow Payment : £1,272,264.63.

Intellectual Property Rights: all existing intellectual property rights including patents, registered and unregistered trademarks and service marks, trade, brand and business names, know how, registered designs and unregistered design rights, copyright, database rights, moral rights (including all such rights in computer software and databases, firmware and other digital material), confidential and proprietary knowledge and information, applications for any of the foregoing, the right to sue for past infringements and the right to apply for or claim priority in respect of any of the foregoing anywhere in the world and all rights of protection of a similar nature to any of the foregoing or having equivalent effect anywhere in the world.

IP Licences: all material licences, agreements, arrangements, authorisations and permissions relating to the use or exploitation-

 

  (a) by the Company of any third party Intellectual Property Rights at the date of this Agreement; and

 

  (b) by any third party of any Company Intellectual Property;

in effect on the date of this Agreement including those listed in the Disclosure Bundle

IT Contracts: all material contracts and agreements relating to the IT Systems used by the Company as at the date of this Agreement but excluding any packaged software, off-the-shelf software, shrink-wrap software or standard form contracts and agreements relating to the IT Systems.

IT Systems: all computer, communications, data processing, electronic and electronic control systems (whether digital or analogue) used by the Company for receiving, processing, storing or transmitting data or instructions, including all website, intranet and extranet files and connections, all computer-aided design and manufacturing equipment and all hardware, software and firmware components of all such systems, but excluding any packaged software, shrink wrap software, standard off-shelf products or other such systems.

 

4


Key Individual: each of Nikin Patel and Shen Luk.

Management Accounts: the unaudited management accounts of the Company as at 31 August 2013 included in the Disclosure Bundle.

Material Contract: each agreement or arrangement listed in Schedule 9 excluding any IP Licences and IT Contracts.

Net Asset Value: has the meaning ascribed to that term in Schedule 6.

Options: any options over Shares granted to any of the Optionholders which are outstanding and capable of exercise prior to Completion or as a result of Completion.

Option Exercise Notice: an exercise notice for Options, as applicable to the relevant Optionholder, in each case in the agreed form set out at Schedule 10.

Optionholder: means each of Nikin Patel, Emma Gainford, Claire Madden-Smith, Shen Luk, Michael Fanfarillo, Robert Harris, Andrew Parker and Steve Kemp.

Pound or £: British Pound Sterling, the lawful currency of the United Kingdom.

Property: means the Company’s freehold properties at Orchard Place Nottingham Business Park registered with title absolute under title numbers NT478638 and NT397462 at the Land Registry.

Purchase Price: the aggregate consideration for all the Shares to be paid by the Buyer to the Sellers in accordance with this Agreement after taking account of all adjustments to such consideration provided for in this Agreement being (prior to any adjustments) £15,903,307.89

Release Dates : the First Release Date and the Second Release Date and each a Release Date.

Relief: any loss, relief, allowance, credit, deduction, exemption or set-off in respect of Tax or relating to the computation of income, profits or gains for the purposes of any Tax or any right to repayment of Tax.

Second Release Date : has the meaning ascribed to that term in clause 10.2.

Securities Act: means the U.S. Securities Act of 1933, as amended.

Seller Proportion : each of the proportions set out in column 7 of the table at Schedule 1.

Sellers’ Representative: the person for the time being filling that role pursuant to clause 14.

Sellers’ Solicitors : Freeth Cartwright LLP of 6 Bennetts Hill, Birmingham, West Midlands B2 5ST.

 

5


Sellers’ Solicitors’ Client Account: Account: 00678613 at Lloyds TSB Bank plc, 39 Threadneedle Street, London EC2R 8AU, Sort Code: 30 00 09 or such other bank account as shall be designated as the Sellers’ Solicitors’ Client Account by written notice to the Buyer’s Solicitors from the Sellers’ Solicitors.

Service Agreement: each service agreement between the Company and a Key Individual in the agreed form.

Share: each issued or allotted share in the capital of the Company as detailed in Schedule 1.

Shareholders Agreement: the shareholders’ agreement dated 20 July 2011 and made between certain of the Sellers and the Company and relating to the Company.

Share Subscription Moneys: in respect of each Unpaid Share, the nominal value and any share premium due to the Company (less any amount already paid up) in respect of the allotment of that Unpaid Share.

Stock Consideration: US$8,299,932.25 to be satisfied by the delivery of 1,051,323 shares of validly issued, fully paid (including any share premium) and non-assessable Columbia Stock, free and clear of any adverse claims (as that term is defined in sections 8 to 102 (inclusive of the Delaware Uniform Commercial Code).

Tax or Taxation: all taxes, duties, levies, social security contributions (including national insurance contributions), imposts, charges, deductions and withholdings of a fiscal nature or in respect of Tax (but excluding any municipal or local government or utility charges), whether created or imposed in the United Kingdom or elsewhere and at whatever time created or imposed which are collected and administered by any Tax Authority and any penalties, interest, fines and default surcharges incidental to or relating to Tax.

Tax Authority: any taxing, governmental, local governmental, fiscal or other authority (whether within or outside the United Kingdom) competent to impose, assess, administer or collect any Tax including H.M. Revenue & Customs.

Tax Claim: a claim under the Tax Indemnity or for breach of any of the Tax Warranties.

Tax Indemnity: the tax covenant as set out in clause 13.

Tax Legislation: any statute, statutory instrument, enactment, law, by-law, directive, decree, ordinance, regulation or other legislative provision imposing or relating to Tax.

Tax Warranties: the Warranties in paragraph 25 of Schedule 4.

TCGA 1992: the Taxation of Chargeable Gains Act 1992.

Unpaid Share: each Share that is not a Fully Paid Share.

 

6


U.S. Person:

 

  (i) Any natural person resident in the United States;

 

  (ii) Any partnership or corporation organized or incorporated under the laws of the United States;

 

  (iii) Any estate of which any executor or administrator is a U.S. Person;

 

  (iv) Any trust of which any trustee is a U.S. Person;

 

  (v) Any agency or branch of a non-United States entity located in the United States;

 

  (vi) Any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. Person;

 

  (vii) Any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; or

 

  (viii) Any partnership or corporation if:

 

  (A) Organised or incorporated under the laws of any jurisdiction outside the United States; and

 

  (B) Formed by a U.S. Person principally for the purpose of investing in securities not registered under the United States Securities Act, unless it is organised or incorporated, and owned, by accredited investors (as defined in § 230.501(a) of that Act) who are not natural persons, estates or trusts.

US$: United States Dollar, the lawful currency of the United States of America.

Warranties: the warranties in clause 8 and Schedule 4.

Warrantor : means each of Nikin Patel, Martyn Davies, Clive Jonathan Roberts and Philip Williams.

Warrantor Proportion : each of the proportions set out in column 8 of the table at Schedule 1.

Waste: all waste, including any unwanted or surplus substance irrespective of whether it is capable of being recycled or recovered or has any value.

Worker: any person other than an Employee who personally performs work for the Company but who is not in business on their own account or in a client/customer relationship.

 

7


2012 Accounts: the audited financial statements of the Company as at and to the 2012 Accounts Date including a balance sheet, profit and loss account together with the notes on them and the directors’ report (copies of which are attached to the Disclosure Letter).

2012 Accounts Date: 31 July 2012.

2013 Accounts: the unaudited balance sheet and profit and loss account of the Company as at and to 31 July 2013 (a copy of which is attached to the Disclosure Letter).

 

1.3 Clause and Schedule headings do not affect the interpretation of this Agreement.

 

1.4 A person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality) and that person’s personal representatives, successors or permitted assigns.

 

1.5 Unless the context otherwise requires, words in the singular include the plural and in the plural include the singular.

 

1.6 Unless the context otherwise requires, a reference to one gender includes a reference to the other genders.

 

1.7 Subject to clause 19, a reference to any party shall include that party’s personal representatives, successors and permitted assigns.

 

1.8 A reference to a company shall include any company, corporation or other body corporate, wherever and however incorporated or established.

 

1.9 A reference to a particular statute, statutory provision or subordinate legislation is a reference to it as it is in force from time to time taking account of any amendment or re-enactment and includes any statute, statutory provision or subordinate legislation which it amends or re-enacts and subordinate legislation for the time being in force made under it, provided that, as between the parties, no such amendment or re-enactment shall apply for the purposes of this Agreement to the extent that it would impose any new or extended obligation liability or restriction on, or otherwise adversely affect the rights of, any party.

 

1.10 Writing or written includes faxes but not e-mail.

 

1.11 Documents in agreed form are documents in the form agreed by the parties or on their behalf and initialled by them or on their behalf for identification.

 

1.12 References to clauses and schedules are to the clauses and schedules of this Agreement; references to paragraphs are to paragraphs of the relevant schedule.

 

8


1.13 References to this Agreement include this Agreement as amended or varied in accordance with its terms.

 

1.14 Any words following the terms including , include , in particular or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms.

 

1.15 Unless specifically provided otherwise, any agreement, covenant, warranty, undertaking or liability arising under this Agreement on the part of two or more persons shall be deemed to be made or given by such persons severally.

 

2. C OLUMBIA S TOCK

 

2.1 Whenever shares of Columbia Stock are required to be delivered pursuant to this Agreement, such shares shall be valued at the Agreed Columbia Stock Price.

 

2.2 Whenever a monetary obligation is required to be satisfied by delivery of shares of Columbia Stock any fractional entitlement to shares of Columbia Stock shall be rounded down to the nearest whole number.

 

2.3 In the event of any stock split, reverse split or consolidation of Columbia Stock, references to Columbia Stock and the Agreed Columbia Stock Price shall be adjusted to reflect the effect of such split, reverse split or consolidation.

 

3. SHARE SUBSCRIPTION MONEYS

Each Seller of Unpaid Shares acknowledges his obligation to pay to the Company the Share Subscription Moneys due in respect of his Unpaid Shares and consents to the same being deducted from the Initial Cash Consideration due to him and paid by the Buyer in accordance with clause 6.2(g) on his behalf to the Company in full and final satisfaction of such obligation.

 

4. S ALE AND PURCHASE

 

4.1 Each of the Sellers shall sell the number of Shares set opposite his name in column 3 of Schedule 1 below with full title guarantee and the Buyer shall buy the Shares on the terms of this Agreement.

 

4.2 The Shares shall be sold free from all Encumbrances and with all rights now or hereafter becoming attached to them.

 

4.3 The Buyer shall not be obliged to complete the sale and purchase of any of the Shares unless the sale and purchase of all of the Shares is completed simultaneously in accordance with this Agreement.

 

9


4.4 Each of the Sellers unconditionally and irrevocably waives all rights and restrictions (including all rights of pre-emption) which may exist for its benefit under the articles of association of the Company or otherwise in respect of the Shares to be sold by it under this Agreement.

 

5. P AYMENT OF P URCHASE PRICE

 

5.1 The consideration for the sale and purchase of the Shares shall be the Purchase Price.

 

5.2 Payment by the Buyer into the Sellers’ Solicitors’ Client Account, the Company’s Account and the Escrow Account in accordance with clauses 6.2(e), 6.2(f) and 6.2(g) shall be a full discharge of the Buyer’s obligation to pay such amounts and the allotment and issue of the shares in Columbia Stock to the Sellers in satisfaction of the Stock Consideration pursuant to clause 6.2(h) and the delivery by the Buyer of certificates in respect of such shares of Columbia Stock to the Sellers’ Solicitors pursuant to clause 6.6 shall be a full discharge of the Buyer’s obligation to deliver such shares of Columbia Stock and the Buyer shall have no further obligation with regard to such amounts and shares of Columbia Stock other than to give instructions to the Escrow Agents in accordance with clauses 7 and 10 below.

 

6. C OMPLETION

 

6.1 Completion shall take place on the Completion Date at the offices of the Buyer’s Solicitors immediately following the execution of this Agreement.

 

6.2 At Completion:

 

  (a) the Sellers shall deliver or cause to be delivered the documents and evidence set out in Part 1 of Schedule 3;

 

  (b) each Party shall do all in its power to cause a directors’ meeting of the Company to be held at which the matters identified in Part 2 of Schedule 3 are carried out;

 

  (c) the Sellers shall deliver any other documents referred to in this Agreement as being required to be delivered by the Sellers at Completion;

 

  (d) the Sellers’ Representative and the Buyer shall enter into the Escrow Agreement with the Escrow Agents;

 

  (e) the Buyer shall pay the Initial Cash Consideration Escrow Payment into the Escrow Account or shall cause the Buyer’s Solicitors to undertake to do so within two Business Days of the Escrow Account being opened and the Buyer’s Solicitors being notified of the relevant sort code and account number;

 

10


  (f) the Buyer shall pay the Initial Cash Consideration On-Account Payment minus the Share Subscription Moneys to the Sellers’ Solicitors’ Client Account;

 

  (g) the Buyer shall pay the Share Subscription Moneys deducted in accordance with clause 3 to the Company’s Account;

 

  (h) the Buyer shall allot and issue to the Sellers the Stock Consideration and deliver to the Sellers’ Solicitors copies (in each case certified to be a true copy by a director or secretary of the Buyer) of a resolution of the Buyer’s board of directors authorising the execution and completion of this Agreement and the payment of the Purchase Price including the payment of the Initial Cash Consideration and the allotment and issue of the Stock Consideration;

 

  (i) the Warrantors shall cause the Company to enter into the Service Agreements with the Key Individuals;

 

  (j) the Buyer shall appoint Dr Nikin Patel to the Buyer’s board of directors; and

 

  (k) the Warrantors shall cause the Company to enter into each Consultancy Agreement.

 

6.3 Following Completion, the Sellers shall deliver or make available (on reasonable notice) to the Buyer all records, correspondence, documents, files, memoranda and other papers relating to and belonging to the Company in their possession not required to be delivered at Completion.

 

6.4 Following Completion the Buyer undertakes that it shall, or shall procure that the Company shall, acting in good faith use its reasonable endeavours to establish a sub-plan of the Buyer’s Amended and Restated 2008 Long-Term Incentive Plan and apply to H.M. Revenue and Customs for the approval of such sub-plan under relevant UK legislation to enable the Company’s employees to participate in such sub-plan in a tax efficient manner.

 

6.5 Without prejudice to their respective rights in respect of accrued remuneration and expenses pursuant to such relationships or arrangements Martyn Davies and Clive Jonathan Roberts each agree with immediate effect on Completion that any relationships or arrangements between them and the Company that are in existence on the Completion Date will terminate including any employment relationship but excluding any new Consultancy Agreement that will be entered into by any of them (or for the avoidance of doubt any person Connected with any of them) with the Company with effect from or after the Completion Date.

 

6.6 Within 7 Business Days of the Completion Date, the Buyer shall deliver to the Sellers’ Solicitors duly executed individual stock certificates in the names of each Seller in respect of each Seller’s entitlement to the Stock Consideration.

 

11


7. P URCHASE P RICE A DJUSTMENT

Within 5 Business Days following the agreement or determination of the Net Asset Value, in either case, pursuant to Schedule 6:

 

7.1 if the Net Asset Value is less than £6,658,000.00 the Purchase Price shall be fixed at the amount of the Initial Consideration minus the shortfall and:

 

  (a) if the credit balance of the Escrow Account is equal to or greater than the shortfall, the Sellers’ Representative and the Buyer shall jointly instruct the Escrow Agents to transfer from the Escrow Account to the Buyer’s Solicitors’ Client Account an amount equal to the shortfall plus an amount stated by the Buyer and the Sellers’ Representative to be equal to the net interest credited to the Escrow Account on the amount of the shortfall from the Completion Date; and

 

  (b) if the credit balance of the Escrow Account is not equal to or greater than the shortfall, the Sellers’ Representative and the Buyer shall jointly instruct the Escrow Agents to transfer the entire credit balance of Escrow Account to the Buyer’s Solicitors’ Client Account and each Covenantor shall, subject to clause 9, pay to the Buyer’s Solicitors’ Client Account his Covenantor’s Proportion of the balance of the shortfall.

 

7.2 For the avoidance of doubt, if the Net Asset Value is not less than £6,658,000 the amount of the Purchase Price shall, subject to clause 7.3, be fixed at the amount of the Initial Consideration.

 

7.3 Any payment made by the Sellers to the Buyer pursuant to a Claim shall, to the extent lawful, be treated as a reduction of the Purchase Price.

 

8. W ARRANTIES

 

8.1 The Buyer warrants to the Sellers that:

 

  (a) it is a corporation duly incorporated, validly existing and in good standing under the laws of Delaware;

 

  (b) it has taken all necessary action and has all requisite power and authority to enter into and perform this Agreement in accordance with its terms and the other documents in the agreed form referred to in it to which it is a party (“ Other Documents ”);

 

  (c) this Agreement and the Other Documents constitute (or shall constitute when executed) valid, legal and binding obligations on itself in the terms of the agreement and such Other Documents.

 

12


  (d) compliance with the terms of this Agreement and, when executed, the Other Documents shall not breach or constitute a default under any of the following:

 

  (i) any agreement or instrument to which it is a party or by which it is bound; or

 

  (ii) any order, judgment, decree, securities exchange rule or listing agreement or other restriction applicable to the Buyer;

 

  (e) it has filed any notice or application required by any market or exchange on which the Columbia Stock is listed or quoted for trading, including the NASDAQ Capital Market, in connection with the issuance and sale of Columbia Stock in satisfaction of the Stock Consideration and will reasonably cooperate to have the Stock Consideration listed on the NASDAQ Capital Market to the extent transfer of the Columbia Stock would be permitted pursuant to Schedule 7; and

 

  (f) the Columbia Stock issued in satisfaction of the Stock Consideration will, when issued, constitute not more than 9% of the issued and outstanding Columbia Stock on a fully-diluted basis.

 

8.2 Each Seller warrants to the Buyer that each Warranty that is expressed in paragraphs 1 and 2.1 of Schedule 4 below is, in relation to himself and his Shares, true and accurate as at immediately prior to Completion.

 

8.3 Each Warrantor warrants to the Buyer that each Warranty, other than the Warranties specified in clause 8.2 above, is true and accurate as at immediately prior to Completion, except as Disclosed.

 

8.4 Warranties qualified by the expression so far as the Warrantors are aware (or any similar expression) are deemed (unless otherwise expressly stated) to be given to the best of the knowledge, information and belief of each Warrantor after he has made reasonable enquiries of each Warrantor and Emma Gainford, Claire Madden-Smith, Shen Luk and Steve Kemp and after he has reviewed all documents received by the Company and in the Company’s possession which are in his reasonable opinion relevant to any of the Warranties.

 

8.5 Each of the Warranties is separate and, unless otherwise specifically provided, is not limited by reference to any other Warranty or any other provision in this Agreement.

 

9. L IMITATIONS ON CLAIMS

 

9.1 A Claim is connected with another Claim if they all arise out of the occurrence of the same event or relate to the same subject matter.

 

13


9.2 This clause limits the liability of the Sellers in relation to claims under this Agreement.

 

9.3 Subject as provided in clause 11.6, the liability of:

 

  (a) each Seller (whether in his capacity as Seller, Covenantor or Warrantor) for all claims pursuant to the terms of this Agreement when taken together shall not exceed that Seller’s Seller Proportion of the Purchase Price (calculated, in respect of any particular such claim as though that claim had not reduced the Purchase Price as contemplated by clause 7.3);

 

  (b) subject always to clause 9.3(a), each Seller for any individual claim pursuant to the terms of clause:

 

  (i) 7.1(a) of this Agreement shall not exceed that Seller’s Seller Proportion in respect of such claim; and

 

  (ii) 7.1(b) of this Agreement shall not exceed that Seller’s Covenantor Proportion in respect of such claim;

 

  (c) subject always to clause 9.3(a), each Warrantor for any individual Claim pursuant to the terms of clause 8.3 and any individual Tax Claim shall not:

 

  (i) in the case of a Claim where a payment is received by the Buyer in respect of such Claim (and to the extent of such payment) from the Escrow Account, exceed that Warrantor’s Seller Proportion in respect of such Claim or Tax Claim; and

 

  (ii) in the case of a Claim where no payment is received by the Buyer in respect of such Claim from the Escrow Account or, to the extent of any balance where any such payment is insufficient to satisfy the liability in respect of such Claim in full, exceed that Warrantor’s Warrantor Proportion in respect of such Claim or Tax Claim.

 

9.4 The Sellers shall not be liable for a Claim unless:

 

  (a) the amount of a Claim, or of a series of connected Claims of which that Claim is one (in each case excluding the costs and interest associated with such Claim), exceeds £635;

 

  (b) the amount of all Claims (excluding the costs and interest associated with such Claim) exceeds £160,000 in which case the whole amount (and not just the amount by which the limit in this clause 9.4(b) is exceeded) is recoverable by the Buyer

provided that this clause 9.4 shall not apply to any claim under the Tax Indemnity or under any of the Warranties expressed in paragraphs 1 and 2.1 of Schedule 4 below.

 

14


9.5 No claim shall be made by the Buyer against the Sellers and the Sellers are not liable for any Claim other than a Tax Claim (Tax Claims shall for the avoidance of doubt be subject to the provisions of clause 13):

 

  (a) to the extent that allowance, provision or reserve was made in the Accounts or Completion Accounts in respect of the matter giving rise to the Claim or otherwise taken into account in their preparation; or

 

  (b) the facts and circumstances giving rise to the Claim were:

 

  (i) Disclosed; or

 

  (ii) disclosed in this Agreement or done in the proper execution and performance of this Agreement; or

 

  (c) to the extent that it occurs or liability is increased as a result of:

 

  (i) an act, omission or transaction done, made or carried out by the Buyer or the Company after Completion outside the ordinary course of the Company’s business save where such act, omission or transaction was required by law or was pursuant to a legally binding commitment of the Company created on or before Completion and save where such act, omission or transaction was carried out by one or more Sellers on the Company’s behalf acting outside the scope of authority of the relevant Seller(s); or

 

  (ii) a change in the accounting reference date of the Company from 31 July; or

 

  (iii) a change in the accounting or Taxation policies or practices of the Company (including the method of submitting Taxation returns and the treatment of timing differences for accounting or Taxation purposes) introduced or having effect after Completion (except where the change is necessary as a result of incorrect policies having been adopted by the Company prior to Completion); or

 

  (iv) any legislation not in force at the date of this Agreement or any change of law or administrative practice (including, in each case, in relation to Taxation) which comes into force after the date of this Agreement; or

 

  (v) any winding up or cessation after Completion of any trade or business carried on by the Company save where such winding up or cessation is caused by the subject matter of one or more claims under the Warranties and/or the Tax Covenant; or

 

  (vi) the failure of the Buyer to comply with its obligations under this clause 9; or

 

15


  (d) which is contingent only unless and until such contingent liability becomes an actual liability and is due and payable; or

 

  (e) if and to the extent that:

 

  (i) the loss in respect of which the Claim is made is recovered under a policy of insurance; or

 

  (ii) the Company or the Buyer has recovered from any third party any sum in respect of loss, damage or liability in respect of which the claim is made

in each case after deducting from such insurance recovery or sum all reasonable and properly incurred costs associated with its recovery, including without limitation any Taxation in respect of it).

 

9.6 The Sellers are not liable for a Claim unless the Buyer has given the Sellers’ Representative notice in writing of the Claim, summarising in reasonable detail the nature of the Claim as far as it is known to the Buyer and the amount claimed:

 

  (a) in the case of a Tax Claim, within the period of five years beginning with the Completion Date (other than claims arising out of the deliberate or careless conduct of the Company);

 

  (b) in the case of a Tax Claim which arises out of the deliberate or careless conduct of the Company, within the period of seven years beginning with the Completion Date; and

 

  (c) in any other case, on or before 31 March 2015.

 

9.7 Subject to clause 13.20, if the Buyer shall become aware of any fact or circumstance which is likely to give rise to a liability of any of the Sellers under the Warranties (and for this purpose the limitations on liability at clause 9.4 shall be ignored) the Buyer shall as soon as reasonably practicable (and in any event within 15 Business Days of becoming so aware) give written notice of it to the Sellers’ Representative, specifying (in reasonable detail with supporting evidence) the event, matter or default which gives rise to the Claim and the Buyer’s best estimate of the amount to be claimed and after that shall keep the Sellers’ Representative informed of all material developments and communications relating to it and the Buyer agrees to give the Sellers’ Representative and his professional advisers reasonable access at any reasonable times and on reasonable advance notice to the premises and personnel of the Buyer and the Company and to any chattels, accounts, documents and records which are relevant to such claim and are within the power or control of the Buyer or the Company (“Relevant Assets”) so as to enable the Sellers’ Representative and his professional advisers to examine such premises, chattels, accounts, documents and records and to take copies at their own expense Provided always that the access to personnel and Relevant Assets granted to the Sellers’ Representative and his professional advisers under this clause 9.7 shall be subject to such reasonable conditions concerning confidentiality and timing as may be required by the Buyer.

 

16


9.8 Any Claim that may have been made shall (if it has not been previously satisfied, settled or withdrawn) be deemed to have been waived or withdrawn on the expiration of 9 months after the latest of:

 

  (a) the date it was notified under clause 9.6;

 

  (b) the date on which the aggregate amount of all single claims exceeds the amount set out at clause 9.4(b) (save that this sub-clause shall not apply for the purpose of applying this clause 9.8 to claims under the Tax Indemnity); and

 

  (c) the date on which a contingent liability that was the subject matter of the Claim became an actual liability that is due and payable provided always that it becomes an actual liability within 3 years of the date it was notified under clause 9.6

unless court proceedings in respect of it shall then have been commenced against the relevant Seller(s) or the Sellers’ Representative and the Buyer shall have agreed in writing to extend such 9 month period in which case this clause 9.8 shall apply to such claim with the substitution of such extended period (and for this purpose court proceedings shall not be deemed to have been commenced unless they have been both issued and served on the appropriate parties). Any Claim based on a contingent liability which does not become an actual liability within 3 years of the date it was notified under clause 9.6 shall be deemed to have been waived or withdrawn on the date which is 3 years and 1 day from the date it was notified under clause 9.6.

 

9.9 For the purpose of the following sub-clauses of this clause 9:

 

  (a) “relevant third party claim” means any claim by a third party against the Buyer and/or the Company which will or is likely to give rise to a claim under the Warranties, other than a claim under any of the Tax Warranties; and

 

  (b) “third party recovery right” means any right to which the Buyer or the Company is or becomes entitled (whether under any insurance policy or by way of payment, discount, credit, set off, counterclaim or otherwise and including a repayment of Tax) to recover from any third party (excluding the Company or the Buyer) any sum (including by way of a reduction in a liability) in respect of any loss, damage or liability which is or is likely to be the subject of a claim against the Sellers under the Warranties, other than a claim under any of the Tax Warranties.

 

17


9.10 Subject to the following sub-clauses of this clause 9 the Sellers’ Representative shall be entitled to require the Buyer to take or procure the Company to take all such steps or proceedings as the Sellers may reasonably consider necessary in order:

 

  (a) to avoid, dispute, resist, mitigate, compromise, defend or appeal against any relevant third party claim;

 

  (b) to enforce any third party recovery right.

Provided that the Buyer shall not be obliged to act in accordance with any such requirement (other than a requirement to enforce a third party recovery right under an insurance policy) unless the Buyer is indemnified to its reasonable satisfaction against all liabilities, costs and incurred or likely to be incurred in connection with the taking of such steps or proceedings.

 

9.11 If at any time the Buyer becomes entitled to recover any sum in respect of any relevant third party claim under a policy of insurance of the Buyer or the Company or from any third party sub-contractor of the Company, the Buyer shall undertake or procure that the Company shall take all reasonable steps necessary to enforce such recovery. The Buyer shall consult in good faith with the Sellers’ Representative in relation to other third party recovery rights and relevant third party claims provided that the Buyer shall not be required to take or procure that the Company shall take any steps or proceedings that would be likely in the reasonable opinion of the Buyer to cause any material damage to any material trading relationship or goodwill of the Buyer or the Company.

 

9.12 The Buyer shall and shall procure that the Company shall:

 

  (a) give notice (containing such details as are reasonably available to it at that time) to the Sellers’ Representative within 15 Business Days of receipt by the Buyer of written notice of any relevant third party claim or third party recovery right or any circumstance giving or likely to give rise to a relevant third party claim coming to its notice;

 

  (b) at all times keep the Sellers’ Representative informed of all material developments and communications relating to that matter;

 

  (c) subject as provided in clause 9.7, give the Sellers’s Representative or his duly authorised representatives reasonable access to the personnel of the Buyer and the Company and to Relevant Assets to enable the Sellers and their duly authorised representatives to investigate any relevant third party claim or any third party recovery right and to examine and take copies or photographs of the Relevant Assets at their own expense;

 

9.13 If any sum shall be recovered by the Buyer from a third party pursuant to a third party recovery right, any Claim by the Buyer in respect of any loss, damage or liability to which the sum relates (other than a claim for breach of a Tax Warranty) shall be reduced by the amount of the sum recovered from the third party after deducting from it any Taxation for which the Buyer may be liable in respect of it and all costs, charges and expenses reasonably incurred by the Buyer in recovering that sum from the third party.

 

18


9.14 If the Sellers shall have paid an amount in respect of a relevant claim which exceeds the amount of that claim as reduced by clause 9.13, the Buyer shall within fifteen Business Days after receiving payment from the relevant third party repay to the Sellers the amount of the excess.

 

9.15 If after the Sellers have made a payment in respect of a Claim for breach of the Warranties other than any of the Tax Warranties, the Buyer or the Company receives from a third party a cash sum or a reduction in a cash liability (whether by payment, discount, credit, set-off or otherwise and including a repayment of Tax or a reduction in a Tax liability) then to the extent that it is referable to that payment or the matter giving rise to the Claim (the “Recovery Amount”) the Buyer shall immediately repay to the Sellers so much of the Recovery Amount (less all taxes, reasonable costs, charges and expenses incurred or required to be paid in respect of such recovery) as does not exceed the sum paid by the Sellers.

 

9.16 The Buyer will not be entitled to recover damages or otherwise obtain reimbursement or restitution or indemnity for more than the amount of any one loss.

 

9.17 Nothing in this Agreement shall operate so as to exclude or limit an individual Seller’s liability in respect of a Claim that arises or is delayed as a result of fraud, wilful or deliberate misconduct or wilful or deliberate concealment by that Seller.

 

9.18 If before 31 March 2015 any Seller becomes actually aware of any fact or matter that is likely to give rise to a Claim, that Seller shall promptly give notice in writing in reasonable detail of that fact or matter to the Buyer and the Sellers’ Representative.

 

9.19 The Sellers shall not plead the Limitation Act 1980 in respect of any Tax Claim.

 

10. E SCROWED F UNDS

 

10.1 Subject as provided in clause 10.4, the Buyer and the Sellers’ Representative shall on the date which is 12 months after the Completion Date (the “First Release Date”) jointly instruct the Escrow Agents to transfer 50% of the credit balance of the Escrow Account plus an amount stated by the Buyer and the Sellers’ Representative to be equal to 50% of the net interest credited to the Escrow Account from the Completion Date to the Sellers’ Solicitors’ Client Account.

 

19


10.2 Subject as provided in clause 10.4, the Buyer and the Sellers’ Representative shall on 31 March 2015 (the “Second Release Date”) jointly instruct the Escrow Agents to transfer the entire credit balance of the Escrow Account to the Sellers’ Solicitors’ Client Account.

 

10.3 If any sums shall remain standing to the credit of the Escrow Account after all Claims notified by the Buyer to the Sellers’ Representative in accordance with clause 9.6 above have been fully and finally resolved pursuant to Clause 11 or Clause 13 or Clause 29 and any amounts due to the Buyer in respect thereof have been paid to the Buyer, the Buyer and the Sellers’ Representative shall as soon as is reasonably practicable jointly instruct the Escrow Agents to transfer the entire credit balance of the Escrow Account to the Sellers’ Solicitors’ Client Account.

 

10.4 In the event a Claim has been notified to the Sellers’ Representative by the Buyer in accordance with clause 9.6 above on or prior to a Release Date then, unless otherwise agreed in writing by the Sellers’ Representative, the Buyer will procure the delivery to the Sellers’ Representative of an opinion from a barrister (approved in writing by the Sellers’ Representative whose approval shall not be unreasonably withheld or delayed) of not less than 10 years call:

 

  (a) as to whether there is a reasonable prospect that liability in respect of the Claim will be established by judgment in favour of the Buyer; and

 

  (b) if there is a reasonable prospect that liability in respect of the Claim will be established by judgment in favour of the Buyer, the reasonable pre-estimate of the quantum of such liability (“Estimated Liability Amount”),

and any payment to be made from the Escrow Account pursuant to clauses 10.1 and/or 10.2 shall only be made if and to the extent that the balance of the Escrow Account immediately following such payment is not less than the aggregate of all Estimated Liability Amounts (save for any Estimated Liability Amount in respect of which the corresponding Claim has been fully and finally resolved pursuant to Clause 11 or Clause 13 or Clause 29 prior to the relevant Release Date). The costs of the barrister shall be apportioned between the Sellers and the Buyer as the barrister shall decide.

 

10.5 Notwithstanding any other provision of this Agreement, if the final resolution pursuant to Clause 11 or Clause 13 or Clause 29 of any Claim in respect of which there is an Estimated Liability Amount requires the payment of any sum (“Actual Liability Amount”) to the Buyer and/or the Company, the Buyer and the Sellers’ Representative shall (subject in each case to the limitations set out in clause 9 above) as soon as practicable following such resolution jointly instruct the Escrow Agents to transfer the (i) Actual Liability Amount plus an amount stated by the Buyer and the Sellers’ Representative to be equal to the net interest credited to the Escrow Account in respect of the Actual Liability Amount from the Completion Date or (ii) (if less) the entire credit balance of the Escrow Account to the Buyer’s Solicitors’ Client Account and the amount so transferred shall, to the extent lawful, be treated as a reduction of the Purchase Price.

 

20


11. C LAIMS

 

11.1 If the Buyer shall notify a Claim to the Sellers’ Representative in accordance with clause 9.6 above, the following provisions shall apply.

 

11.2 The Buyer and the Sellers’ Representative shall negotiate in good faith with a view to reaching agreement as to the validity of the Claim and the liability (if any) of the Sellers in respect of such Claim and, if and to the extent, such agreement is reached, the Buyer and the Sellers’ Representative shall jointly notify the Sellers of the terms so agreed which shall be binding on the Buyer and the Sellers.

 

11.3 If the Buyer and the Sellers’ Representative shall fail to reach agreement within 40 Business Days following notification of the Claim in accordance with clause 9.6 above, the Buyer shall, subject to clause 9, be entitled to pursue the Claim in accordance with clause 29.

 

11.4 If the terms on which a claim against a Covenantor (whether in his capacity as Seller, Covenantor or Warrantor) under this Agreement has been fully and finally resolved pursuant to Clause 11 or Clause 13 or Clause 29 require the Covenantor to make a payment to the Buyer or the Company before the first anniversary of Completion and the amount of such claim is not fully satisfied by means of a payment to the Buyer and/or the Company from the Escrow Account pursuant to clause 10.5 the balance outstanding of such claim (subject in each case to the limitations set out in clause 9 above) shall be satisfied as follows:

 

  (a) each Covenantor who is liable for all or part of such balance shall return to the Buyer, and the Buyer shall accept, shares of Columbia Stock that were received by that Covenantor as Stock Consideration in or towards satisfaction of such Covenantor’s portion (giving due effect to such Covenantor’s Covenantor Proportion or Warrantor Proportion as applicable) of such balance which shall be accomplished by the relevant Covenantor delivering to the Buyer the share certificate for that Covenantor’s portion of the Stock Consideration and (if the amount of such balance applicable to such Covenantor is less than the value of such Covenantor’s portion of the Stock Consideration) the Buyer shall deliver a new share certificate to such Covenantor for a number of shares of Columbia Stock with a value equal to the difference between the amount of such balance applicable to such Covenantor and the value of such Covenantor’s portion of the Stock Consideration; and

 

21


  (b) if such balance was not fully satisfied by the delivery of shares of Columbia Stock pursuant to paragraph (a) above, the remaining balance shall be due from each relevant Covenantor to the Buyer as a debt according to such Covenantor’s Covenantor Proportion or Warrantor Proportion (as applicable).

 

11.5 For the avoidance of doubt all deliveries of shares of Columbia Stock for the purposes of clause 11.4 shall be valued at the Agreed Columbia Stock Price.

 

11.6 Whenever a Covenantor (whether in his capacity as Seller, Covenantor or Warrantor) is due to make a payment in respect of any claim under this Agreement (not being a claim to which clause 11.4 applies) after the total amount paid to the Buyer and/or the Company in respect of that Covenantor’s liability for claims under this agreement has exceeded that Covenantor’s Seller Proportion of the Initial Cash Consideration, the application of that Covenantor’s overall maximum liability for all claims pursuant to clause 9.3(a) shall be determined after adjusting that Covenantor’s Seller Proportion of the Purchase Price in accordance with the following formula:

A – B + C = Covenantor’s adjusted Seller Proportion of the Purchase Price

Where

A = the amount in Pounds of the relevant Covenantor’s Seller Proportion of the Purchase Price before giving effect to the adjustment;

B = the Agreed Columbia Stock Price multiplied by the number of shares of Columbia Stock that were received by that Covenantor as Stock Consideration and that are still held by the Covenantor on the due date for payment of the relevant claim ( “Retained Columbia Shares” ) converted to Pounds at the spot rate published in the Financial Times on the date soonest before the due date for payment of the relevant claim; and

C = the aggregate value of the Retained Columbia Shares calculated by reference to closing price of Columbia Stock on the trading day soonest before the due date for payment of the relevant claim converted to Pounds at the spot rate mentioned in B

Provided that if applying such formula on any occasion would result in the relevant Covenantor’s Seller Proportion of the Purchase Price being greater than the amount of his Seller Proportion of the Purchase Price on the Completion Date, the adjustment shall not be made on that occasion.

 

22


12. GROSS UP

 

12.1 Any payment made in accordance with the provisions of this Agreement (other than any payment in respect of which there is an express right of set off under this Agreement) shall be paid without deduction, counterclaim, set off or withholding except as may be required by law. If any deduction or withholding is required by law, the person making the payment (other than any payment of the Purchase Price or any element thereof pursuant to this Agreement or any payment of interest) shall pay such sum as will, after such deduction or withholding, leave the recipient with the same amount it would have been entitled to in the absence of the requirement to make a deduction or withholding.

 

12.2 Any payment made in accordance with the provisions of this Agreement (other than the Purchase Price or any element thereof or any payment of interest) shall include any amount necessary to ensure that, after any Taxation of the payment, the recipient is left with the same amount it would have had if the payment was not subject to Taxation.

 

12.3 If the Buyer assigns the benefit of this Agreement, the Sellers shall not be liable pursuant to clause 12.1 or clause 12.2 save to the extent that the Sellers would have been so liable had no assignment occurred.

 

13. T AX INDEMNITY , T AX C OMPLIANCE AND A CCESS TO I NFORMATION

 

13.1 Subject to clause 13.7 and the relevant provisions of clause 9 above, the Warrantors covenant with the Buyer to pay to the Buyer an amount equal to the amount of any liability of the Company:

 

  (a) to make or suffer an actual payment of Tax arising in respect of or in consequence of:

 

  (i) any income, profits or gains earned, accrued or received (or deemed to be earned, accrued or received) by the Company on or before Completion; or

 

  (ii) any transaction, circumstance or event which occurred (or is deemed to have occurred) on or before Completion; or

 

  (b) to make or suffer an actual payment of Tax properly attributable to any of the Warrantors or which would not have arisen but for the relationship prior to Completion for Tax purposes of the Company with any person other than a member of the Buyer’s Tax Group, whenever arising provided that “relationship” for this purpose shall mean either (a) connected for the purposes of section 1122 CTA 2010 or (b) associated for the purposes of section 455 CTA 2010;

 

  (c) to make or suffer an actual payment of Tax arising in respect of or in consequence of any of the circumstances set out in clause 13(a)(i) or 13(a)(ii) above, as a result of any claim made by the Company under Part 13 of the CTA 2009 on or before Completion for corporation tax relief in respect of expenditure for research and development being wholly or partially disallowed by any Tax Authority; or

 

23


  (d) to make or suffer an actual payment of Tax arising in respect of or in consequence of the exercise of the Options,

save in each case to the extent that the Tax has been discharged before Completion, together with all reasonable costs and expenses properly incurred by any member of the Buyer’s Tax Group in connection with any liability to Tax for which the Warrantors are liable under this Tax Indemnity and the successful enforcement of rights under this Tax Indemnity.

 

13.2 The Warrantors covenant with the Buyer to pay to the Buyer an amount equal to the amount of any liability for inheritance tax which:

 

  (a) is a liability of the Company and arises as a result of a transfer of value occurring or being deemed to occur on or before Completion (whether or not in conjunction with the death of any person whensoever occurring); or

 

  (b) arose on or before Completion (whether or not a liability of the Company) and gives rise to a charge on any of the Shares or assets of the Company; or

 

  (c) arises after Completion and gives rise to a charge on any of the Shares or assets of the Company as a result of the death of any person within seven years of a transfer of value which occurred on or before Completion;

 

13.3 For the purpose of clause 13.1 the liability to make or suffer an actual payment of Tax shall include:

the use or set off of

 

  (a) any Relief arising to the Company in respect of a transaction, circumstance or event occurring after Completion or attributable to any accounting period commencing after Completion or the post-Completion part of the account period current at Completion (but excluding a Relief which constitutes a Saving for the purposes of sub-clause 13.12 below);

 

  (b) any Relief arising to any member of the Buyer’s Tax Group (other than the Company);

in circumstances where, but for such use or set-off, the Company would have been liable to make an actual payment of Tax for which the Warrantors would have been liable under clause 13.1 or 13.2 above in which case the amount of the deemed liability to make an actual payment of Tax is the amount of Tax or increase to the amount of Tax for which the Warrantors would have been liable had such set off or use not taken place.

 

24


13.4 For the purposes of clause 13.2 the provisions of section 213 of the Inheritance Act 1984 shall be deemed not to apply to any liability to inheritance tax.

 

13.5 Any reference to a transaction, circumstance or event which occurred (or is deemed to have occurred) on or before Completion shall include a series or combination of transactions, circumstances or events where one of which occurred (or is deemed to have occurred) on or before Completion outside the ordinary course of business of the Company (as carried on by it at that time) and those occurring on or after Completion are in the ordinary course of business (as carried on at the date of Completion).

 

13.6 For the purposes of determining in this clause 13 whether any income, profits or gains (whether actual or deemed) have been earned, accrued or received (or any other transaction, circumstance or event, whether actual or deemed, has occurred, or any Relief has arisen) on or before Completion, an accounting period of the Company shall be deemed to have ended on Completion.

Exclusions and limitations

 

13.7 The covenants in clauses 13.1 or 13.2 shall not apply to any liability or increase of any liability, and the Warrantors shall not be liable for any claim for breach of any of the Tax Warranties, to the extent that:

 

  (a) the liability is specifically provided for in the Completion Accounts or was otherwise reflected in the Completion Accounts so as to reduce the value of the Company’s assets;

 

  (b) the liability arises or is increased as a result of any change in rates of Tax made after Completion or of any change in law, regulation or published practice of any Tax Authority occurring after Completion;

 

  (c) the liability would not have arisen or been increased but for any change after Completion in the accounting period or accounting practice or principles of the Company or date to which the Company makes up its accounts for Tax purposes (other than to comply with generally accepted accounting principles);

 

  (d) the liability would not have arisen or not have been increased but for the association after Completion of the Company with the Buyer or any member of the Buyer’s Tax Group;

 

25


  (e) any Relief other than any Relief falling within clause 13.3 is available to reduce or eliminate such liability, to the extent that its availability has not been used under this clause 13.7 (e) to limit another liability of the Warrantors;

 

  (f) the liability has been made good or the Buyer or the Company has been compensated in respect of it at no expense to the Buyer or the Company;

 

  (g) the liability would not have arisen but for a voluntary act, transaction or omission of the Company outside the ordinary course of its business carried out or effected after Completion and which act, transaction or omission the Company or the Buyer was aware (or should reasonably have been aware) would give rise to the liability, save where such act, transaction or omission occurs pursuant to a legally binding obligation of the Company entered prior to Completion or with the written approval or at the written request of the Sellers’ Representative;

 

  (h) where a claim is made for breach of any of the Tax Warranties (but not under clause 13.1 or 13.2), the facts and circumstances giving rise to the relevant liability have been Disclosed;

 

  (i) such liability to Taxation constitutes a fine, penalty, surcharge or interest arising solely by reason of any failure or delay on the part of the Buyer or the Company in paying over to the relevant Tax Authority any payment made by the Warrantors under clause 13.1 or 13.2 or in keeping, preserving, maintaining or submitting any account form or return after Completion;

 

  (j) the liability would not have arisen or would have been reduced but for a failure or omission on the part of the Buyer or the Company to make any election or claim any Relief the making or claiming of which was specifically taken into account in computing the provision or reserve for Tax in the Completion Accounts (or in determining that no provision or reserve for Tax was required in the Completion Accounts);

 

  (k) the liability arises (or is increased) solely by reason of a voluntary disclaimer by the Company after Completion of the whole or any part of any allowance to which it is entitled under the Capital Allowances Act 2001 and which it has actually claimed on or prior to Completion or by reason of the revocation by the Company after Completion of any claim for relief actually made prior to Completion;

 

26


  (l) the liability would not have arisen or would have been reduced but for a cessation of or any change in the nature or conduct of any trade carried on by the Company being a cessation or change occurring on or after Completion;

 

  (m) the liability arises or is increased solely as a consequence of any failure by the Buyer or the Company to comply with any of their respective obligations under clauses 13.20 to 13.36 of this Agreement;

 

  (n) the liability relates to a liability for Taxation which was discharged on or before Completion and the discharge of such liability to Taxation was specifically reflected in the Completion Accounts;

 

  (o) the liability for Taxation arises from or is increased by any income profits or gains which are deemed to arise for or be received by the Company before Completion but which are actually received by or actually arise for the Company after Completion and which are not taken into account in the Completion Accounts;

 

  (p) the liability consists of an underpayment of corporation tax by instalments due to the Company’s taxable profits for the period after Completion being greater than they were anticipated to be at the start of the current accounting period;

 

  (q) the liability is attributable to the Company ceasing to be entitled to the small companies rate of corporation tax as a result of the purchase of the Shares by the Buyer.

Date of Payment

 

13.8 The Warrantors shall pay to the Buyer any amount under clause 13.1 or 13.2 within 5 (five) Business Days after demand is made for that payment by the Buyer or, if later, on or prior to the date which is 5 (five) Business Days before:

 

  (a) the latest date on which an actual payment relating to the relevant liability is due to be made to the relevant Tax Authority in order to prevent a liability to interest or a fine, surcharge or penalty from arising in respect of the liability for Taxation in question (or would have been so due but for the loss, use or set-off of a Relief in accordance with clause 13.3); or

 

  (b) in the case of a payment of costs and expenses pursuant to 13.1, the latest date on which the cost or expense in question is required to be payable to the third party in question on the usual terms for the supply of services by that party to the relevant member of the Buyer’s Tax Group.

 

27


13.9 Where payment of any amount due under clause 13.1 or 13.2 of this tax covenant is satisfied by the use of monies held in the Escrow Account pursuant to clause 10 of the Agreement, to that extent the liability of the Warrantors to make payment under clause 13.1 or 13.2 shall be treated as satisfied for all purposes of this clause 13.

Overprovisions and Savings

 

13.10 Upon the Company or the Buyer becoming aware that any provision for tax in the Completion Accounts has been or is likely to have been an over-provision, the Buyer shall as soon as reasonably practicable give notice (including reasonable details) of that fact to the Sellers’ Representative and if the Expert certifies that there has been an over-provision, then the amount of such over-provision shall constitute a “Saving” for the purposes of sub-clause 13.12 below.

 

13.11 If the Expert certifies (at the request and expense of the Warrantors) that any liability for Tax (or the subject matter giving rise to it) which has resulted in a payment becoming due under this clause 13 will give rise to a Relief or right to repayment of Tax which would not otherwise have arisen then, provided the Warrantors shall have paid the amount due under this clause in respect of the liability, as and when the liability of the Company to make an actual payment of Tax is reduced by reason of that Relief or as and when the repayment of Tax occurs, the amount by which that liability is reduced or the amount of the repayment shall constitute a “Saving” for the purposes of sub-clause 13.12 below.

 

13.12 The amount of any Saving shall first be set off against any payment then due from the Warrantors under this clause (such amount set off to be treated as payment by the Warrantors for all purposes of this Agreement) and to the extent there is an excess of Saving, a refund shall be made to the Warrantors by the Buyer as soon as reasonably practicable thereafter to the extent of (and solely to the extent of) any payments previously made by the Warrantors under this clause 13 (and not previously repaid) and to the extent that such excess is not exhausted, the remainder shall be carried forward and set off against any future payment or payments which become due from the Warrantors under this clause 13 (such set off, as and when it takes place, to be treated as payment by the Warrantors for all purposes of this Agreement).

 

13.13 Where any certification pursuant to sub-clause 13.10 or 13.11 above has been made, the Sellers’ Representative or the Buyer may request the Expert to review such certification in the light of subsequent events and to certify whether the amount that was the subject of the certification should be amended. If the Expert certifies that any amount should be amended, such adjusting payment as may be required by virtue of this amendment shall be made as soon as practicable by or (as the case may be) to the Warrantors.

 

28


13.14 For the purposes of this clause “the Expert” means an independent accountant specialising in the field of taxation relevant to the issue who is agreed upon between the parties or, in the absence of agreement, who is appointed by the President for the time being of the Institute of Chartered Accountants in England and Wales. The Experts certificate shall (in the absence of manifest error) be conclusive and binding on all concerned.

 

13.15 Following exercise of the Options prior to Completion, to the extent that the Company shall receive:

 

  (a) and retain the benefit of a corporation tax deduction in respect of the exercise of the Options (the “Deduction”), the liability of the Warrantors to make a payment under clause 13.1 shall be reduced to the extent that any Tax liability giving rise to the Warrantors’ liability under clause 13.1 is reduced by the use or set off of the Deduction;

 

  (b) payment or credit in satisfaction of the exercise price due from any Optionholders upon exercise of the Options (the “Options Payment”), the Options Payment shall be set off against any payment due from the Warrantors under clause 13.1 in relation to a liability to Tax arising in respect of or in consequence of the exercise of the Options as and when such payments are required to be made (such set off, as and when it takes place, to be treated as payment by the Warrantors for all purposes of this Agreement) until such time as the Options Payment is exhausted.

For the purposes of clause 13.15(a) the Buyer agrees to procure that the Company shall use all reasonable endeavours to use or set off the Deduction (including, without limitation, the carry back of the Deduction if appropriate), in priority to the utilisation of any other Relief, to the fullest extent possible against any Tax liabilities of the Company which give rise to the Warrantors’ liability to make a payment under clause 13.

Recovery from third parties

 

13.16 If the Company recovers from any other person (including without limitation any Tax Authority but excluding the Buyer and any other member of the Buyer’s Tax Group) any amount which is referable to a liability to Taxation or other liability of the Company in respect of which the Warrantors have made a payment in respect of a Tax Claim, the Buyer will repay to the Warrantors the lesser of:

 

  (a) the amount so recovered (less any losses, costs, damages and expenses reasonably incurred by the Company, the Buyer or any other member of the Buyer’s Tax Group in effecting the recovery of that amount and less any Tax arising in respect of the amount recovered save to the extent any such losses, costs, damages, expenses or Tax have been reimbursed by the Warrantors); and

 

29


  (b) the amount paid by the Warrantors under clause 13.1 or 13.2 or the Tax Warranties (as the case may be) in respect of the liability to Taxation or other liability in question less any part of such amount previously repaid to the Warrantors under any provision of the Agreement.

 

13.17 If the Buyer becomes aware that the Company is entitled to recover from other persons, excluding the Buyer and any other member of the Buyer’s Tax Group and any of the Company’s officers or employees, any amount mentioned in clause 13.16, the Buyer will as soon as reasonably practicable give notice of that fact to the Sellers’ Representative and provided that the Warrantors indemnify the Company, the Buyer and all other members of the Buyer’s Tax Group to the reasonable satisfaction of the Buyer against all reasonable costs and expenses which may be properly incurred thereby and against all losses and damages (including any additional Tax), the Buyer will procure that the Company, at the Warrantors’ costs and expense, promptly takes such action as the Sellers’ Representative may reasonably request to effect such recovery, provided that nothing in this clause 13.17 shall require any person to take any action which, in the Buyer’s reasonable opinion, is likely to be materially prejudicial to the goodwill of the business or financial interests of the Company or the Buyer or any other member of the Buyer’s Tax Group.

Repayments of tax

 

13.18 If the Company receives any actual repayment of Taxation which relates to a period prior to Completion which is not a Relief falling within clause 13.3 above or constituting a Saving for the purposes of clause 13.12 (including any such receipt on behalf of the Company by any member of the Buyer’s Tax Group) and which has not been taken into account in the Completion Accounts) (a “Repayment”), (and for the purposes of this clause a Repayment shall include both an actual repayment and a right to repayment being given effect by way of an immediate offset against any Tax liability of the Company or any other member of the Buyer’s Tax Group then outstanding which is due and payable) the Buyer will as soon as is reasonably practicable thereafter repay to the Warrantors the lesser of:

 

  (a) the amount of the Repayment (net of any Tax or other costs of receipt); and

 

  (b) the aggregate amount (if any) paid by the Warrantors under clause 13 less any part of that amount previously paid to the Warrantors under any provision of this Agreement;

 

30


13.19 If upon receipt of a Repayment pursuant to paragraph 13.18 the amount mentioned in paragraph 13.18(a) exceeds the amount mentioned in paragraph 13.18(b) the excess will be set against (and so will reduce or eliminate) any liability of the Warrantors under this clause 13 then outstanding or which arises after such determination, in the latter case as and when such liability arises.

Conduct of claims

 

13.20 Upon the Buyer or the Company becoming aware of any matter giving rise to a Tax Claim or becoming aware that a liability has arisen in respect of which the Buyer is entitled to payment under this clause 13 or for breach of any of the Tax Warranties, the Buyer shall forthwith give written notice thereof (to include reasonable details of the liability in question and how such liability has been calculated, to the extent that such information is available to the Buyer) to the Warrantors’ Representative, provided that the giving of such notice shall not be a condition precedent to the Warrantors’ liability under this Agreement.

 

13.21 On receiving the notice referred to in clause 13.20, the Buyer shall procure that the Company shall promptly take such action including the non-payment of a Tax liability and give such information and assistance in connection with the affairs of the Company as the Sellers’ Representative may reasonably request, subject to the provisions of clause 13.22 and provided that the Warrantors shall have first indemnified the Buyer to its reasonable satisfaction against all reasonable losses, costs, damages and expenses, including any additional Tax and interest on overdue Tax, which may be properly incurred thereby (such a Tax Claim where action is so requested by the Warrantors shall hereafter be referred to as a “Dispute”).

 

13.22 The Buyer shall not be required to take any action or further action under clause 13.21 and shall instead be entitled, without reference to the Warrantors, to admit, compromise, settle, discharge or otherwise deal with the relevant liability on such terms as it may in its absolute discretion think fit and without prejudice to any right or remedy under this Agreement, if any of the following circumstances apply:

 

  (a) it appears to the Buyer or the Company (in each case acting reasonably) that while the Company was under the control of the Sellers there was any act or failure to act by the Company or the Sellers which constituted fraud in relation to the relevant liability;

 

  (b) on receipt of the notice referred to clause 13.20 the Sellers’ Representative has failed to give written notice to the Buyer of the action they request the Buyer to take in accordance with clause 13.21 within 15 (fifteen) Business Days where the time limit for making the appeal is 30 days or within 20 (twenty) Business Days in any other case;

 

31


  (c) the action requested by the Sellers’ Representative under clause 13.21 would, in the Buyer’s reasonable opinion, be materially prejudicial to the goodwill of the business or financial interests of the Company or any member of the Buyer’s Tax Group;

 

  (d) the action requested by the Sellers’ Representative under clause 13.21 would involve proceedings before any court, tribunal or other appellate body (other than the relevant Tax Authority), unless the Sellers’ Representative has (at the Sellers’ expense) been advised in writing by tax counsel who has specialised in Tax matters for a minimum of 10 (ten) years, after disclosure of all relevant information and documents, that it is reasonable to take the action requested by the Sellers’ Representative and has provided such advice to the Buyer no later than seven days prior to the date of the first hearing by the relevant court, tribunal or other appellate body to hear the substantive issues of the appeal but provided for the avoidance of doubt that this sub-clause shall not apply to any request from the Sellers’ Representative to (i) serve notice of an appeal or (ii) to take any appropriate preparatory or procedural steps prior to any hearing of an appeal (except any such steps to be taken within seven (7) days before the date of the hearing).

 

13.23 Subject to clause 13.22, the following shall apply:

 

  (a) the Buyer shall procure that the Company shall promptly keep the Sellers’ Representative fully informed of all matters pertaining to a Dispute and shall procure that the Sellers’ Representative shall see and keep copies of all material correspondence and notes or other written records of meetings or material telephone conversations and, in the event that there is no written record, shall be promptly given a report of any material telephone conversation with any Tax Authority to the extent that it relates to a Dispute;

 

  (b) all material written communications pertaining to the Dispute which are to be transmitted to the relevant Tax Authority shall first be submitted to the Sellers’ Representative for approval and shall only be finally transmitted if such approval is given (and subject to such amendments as may reasonably be requested by the Sellers’ Representative) such approval not to be unreasonably withheld or delayed; and

 

32


  (c) the Buyer shall procure that no settlement or compromise of the Dispute or agreement to any matter which is likely to affect the amount thereof or the existence or amount of any liability of the Warrantors is made without the prior written approval of the Sellers’ Representative such approval not to be unreasonably withheld or delayed.

 

13.24 Where any Warrantor is subject to legal proceedings to make that Warrantor bankrupt, or is unable to pay his debts as they fall due, that Warrantor shall lose any further rights under clause 13.21, but without prejudice to the rights of the other Warrantors.

Tax returns

 

13.25 Subject as provided elsewhere in this clause 13, the Sellers’ Representative or their duly authorised agent shall at the Company’s expense prepare the Tax returns of the Company and other necessary documentation relating thereto for all accounting periods ended on or before Completion (the “ Pre-Completion Periods ”) and shall deal with all matters (including correspondence and audits) relating to those Tax returns (to the extent that such returns have not yet been finalised and agreed with the relevant Tax Authority).

 

13.26 All Tax returns and other documents relating to the Pre-Completion Periods shall be prepared in a manner consistent with past practices and without any change of accounting method (except to the extent necessary to comply with applicable laws or with the written consent of the Buyer (such consent not to be unreasonably withheld or delayed) and shall be submitted in draft form to the Buyer for comment at least twenty (20) Business Days before the expiry of any time limit for the submission of such document to the relevant Tax Authority. The Buyer shall comment within ten (10) Business Days of such submission and the Sellers’ Representative shall not unreasonably refuse to adopt such comments. The Buyer shall not without the written consent of the Sellers’ Representative amend the same (such consent not to be unreasonably withheld or delayed).

 

13.27 The Buyer shall, or shall procure that the Company shall, cause any returns prepared and finalised in accordance with clauses 13.25 and 13.26 to be authorised, signed and submitted to the appropriate Tax Authority without delay, provided that the Buyer and the Company shall not be required to submit any documents which in the Buyer’s reasonable opinion are not full, true and accurate in all material respects. The Buyer shall, or shall procure that the Company shall, provide the Warrantors with all such reasonable assistance as may be required to agree those returns with the appropriate Tax Authority.

 

13.28

The Sellers’ Representative shall keep the Buyer and the Company fully informed of all matters and developments relating to the Tax returns and other documents for any Pre-Completion Period for which final agreement with the relevant Tax Authority of the amount of Tax due from the Company has not

 

33


  been reached and will not submit any correspondence or submit or agree any return or computation for any such period to or with any Tax Authority without giving the Buyer a reasonable opportunity to comment and taking account of any such comments insofar as they are reasonable.

 

13.29 The Buyer shall, or shall procure that the Company shall, promptly afford the Sellers’ Representative such access to its books, accounts and records as is necessary and reasonable to enable the Sellers’ Representative or their duly authorised agents to prepare and file Tax returns and conduct matters relating thereto in accordance with the Sellers’ Representative’s rights under clause 13.25 above and, in particular, in relation to the Tax returns and conduct of matters relating thereto for the accounting period ended 31 July 2013 (the “2013 Return”) the Buyer shall, or shall procure that the Company shall, provide all reasonable help and assistance needed to prepare, submit and agree the 2013 Return.

 

13.30 The Buyer shall give the Sellers’ Representative and shall procure that the Sellers’ Representative is promptly given reasonable access to all books, accounts and records of the Company which are handed over to the Buyer at Completion as may be reasonably required by the Sellers’ Representative for the purposes of the Sellers’ Tax affairs.

 

13.31 The Warrantors (through the Sellers’ Representative) shall give the Buyer and shall procure that the Buyer is given reasonable access to all books, accounts and records of the Company which are not handed over to the Buyer at Completion and shall give the Buyer such other assistance as may be reasonably required to enable the Buyer to prepare accurate corporation tax returns for the Company for all relevant periods and to ensure that all Tax compliance obligations of the Company are properly discharged.

 

13.32 The Buyer or its duly authorised agent shall at the Company’s expense prepare the Tax returns of the Company and other necessary documentation relating thereto for the accounting period which is current at Completion (the “ Straddle Period ”) and shall deal with all matters (including correspondence and audits) relating to those Tax returns (to the extent that such returns have not yet been finalised and agreed with the relevant Tax Authority).

 

13.33 All Tax returns and other documents relating to the Straddle Period shall be prepared in a manner consistent with past practices and without any change of accounting method (except to the extent necessary to comply with applicable laws or with the Sellers Representative’s consent (not to be unreasonably withheld)) and shall be submitted in draft form to the Sellers’ Representative for comment at least twenty (20) Business Days before the expiry of any time limit for the submission of such document to the relevant Tax Authority (with working papers used to produce the same and any supporting documentation). The Sellers’ Representative shall comment within ten (10) Business Days of such submission and the Buyer shall not unreasonably refuse to adopt such comments and reasonable amendments suggested by the Warrantors to the extent that they relate to such part of the Straddle Period falling prior to Completion.

 

34


13.34 The Buyer shall keep the Sellers’ Representative fully informed of all matters and developments relating to the Tax returns and other documents for the Straddle Period for which final agreement with the relevant Tax Authority of the amount of Tax due from the Company has not been reached and will not submit any correspondence or submit or agree any return or computation for, or relating to, that part of the Straddle Period falling prior to Completion to or with any Tax Authority without giving the Sellers’ Representative a reasonable opportunity to comment and taking account of any such comments insofar as they are reasonable.

 

13.35 Subject to clauses 13.25 to 13.34, the Buyer shall have exclusive conduct of all Tax affairs of the Company after Completion.

 

13.36 The Buyer shall procure that the Company shall not file an amended corporation tax return or computation for any period ending on or before Completion or any period in which Completion falls without having complied in full with its obligations under this clause 13, provided that if it appears that any Tax return or other necessary documentation for any Pre-Completion Period or the Straddle Period will give rise to a Tax Claim the provisions in clauses 13.20 to 13.24 (Conduct of Claims) shall take precedence over the provisions in clauses 13.25 to 13.35.

Buyer’s covenant

 

13.37 The Buyer covenants with and undertakes to the Warrantors to pay to the Warrantors an amount equal to any Taxation which is assessed under section 710 or section 713 CTA 2010 or arising under section 189 or section 190 TCGA or section 109E TMA 1970 (as inserted by paragraph 54 Schedule 7 TIOPA 2010) or any other legislation on any of the Warrantors by reason of Taxation assessed on the Company being unpaid other than any Taxation the liability for which falls upon the Warrantors pursuant to the Tax Indemnity in this clause (unless the Warrantors have made payment to the Buyer in respect of such liability) or which would fall upon the Warrantors but for the application of clause 9 ( Limitations on Claims) and:

 

  (a) this covenant shall apply to any reasonable costs and expenses incurred by the Warrantors in connection with any such Taxation;

 

  (b) the due date for payment of any amount payable pursuant to this clause 13.37 will be the later of the date falling 5 (five) Business Days before the party so assessed is obliged to pay the Tax and other liabilities in question and the date falling 5 (five) Business Days after the Warrantors have served notice on the Buyer demanding such payment.

 

35


13.38 The Warrantors covenant that they shall make no claim under clause 13.37 above to the extent that they shall have recovered the Taxation in question under section 717 CTA 2010 and that to the extent that it recovers any amount under clause 13.37 above they shall not seek to recover payment under section 717 CTA 2010.

 

14. S ELLERS ’ R EPRESENTATIVE

 

14.1 Unless and until he is prevented from acting as such by illness, injury, mental incapacity or death, the Sellers’ Representative shall be Professor Martyn Christopher Davies.

 

14.2 In the event that the Sellers’ Representative is prevented from acting as such by illness, injury, mental incapacity or death the other Sellers who are not so affected shall, as soon as is reasonably practicable, appoint a replacement Sellers’ Representative and notify the Buyer of the identity of such replacement Sellers’ Representative.

 

14.3 If the relevant Sellers are unable to reach a unanimous decision as to a replacement Sellers’ Representative, they shall decide by simple majority on the basis of one vote for every Share as specified in Schedule 1.

 

14.4 The Sellers irrevocably appoint the Sellers’ Representative as their attorney for an on their behalf to make all decisions, execute all deeds and documents and conduct all negotiations with the Buyer and/or the Company in connection with this Agreement and the Sellers shall be bound by all acts and decisions of the Sellers’ Representative in connection therewith.

 

14.5 The Buyer and the Company shall be entitled to deal with the Sellers’ Representative as the attorney of the Sellers in connection with this Agreement.

 

14.6 Whenever a new Sellers’ Representative is appointed during the subsistence of the Escrow Agreement, the Sellers’ Representative and the Buyer shall co-operate in good faith to ensure that the functions of the Sellers’ Representative in relation to the Escrow Agreement are effectively assumed by the new Sellers’ Representative.

 

36


15. R ESTRICTIONS ON THE C OVENANTORS

 

15.1 Except in the proper performance of his employment by the Company or the Buyer’s Group, each Covenantor covenants with the Buyer that he shall not:

 

  (a) at any time during the period of two years beginning with the Completion Date carry on or be employed, engaged or interested, in or provide consultancy services in relation to any of the following business activities: pharmaceutical analysis, pharmaceutical development, clinical trial manufacture/packaging, pharmaceutical litigation; or

 

  (b) at any time during the period of two years beginning with the Completion Date, deal with any person who is at the Completion Date, or who has been at any time during the period of 12 months immediately preceding that date, a client or customer of the Company in relation to a business which is in competition with all or part of the business carried on by the Company at the Completion Date; or

 

  (c) at any time during the period of two years beginning with the Completion Date, canvass, solicit or otherwise seek the custom of any person who is at the Completion Date, or who has been at any time during the period of 12 months immediately preceding that date, a client or customer of the Company in relation to a business which is in competition with all or part of the business carried on by the Company at the Completion Date; or

 

  (d) at any time during the period of two years beginning with the Completion Date:

 

  (i) attempt to entice away from the Company, any individual who is, at the time of the attempt, employed directly or indirectly or otherwise engaged in a senior, executive, managerial, technical or scientific position with the Company; or

 

  (ii) procure or facilitate the making of any such attempt by any other person; or

 

  (e) at any time after Completion, use in the course of any business other than the Company’s and/or Buyer’s Group business:

 

  (i) the words “Molecular Profiles” “Columbia”, “Crinone” or “Striant”, “Prochieve”, “Replens”, “RepHresh” or any confusingly similar name; or

 

  (ii) any trade or service mark, business or domain name, design or logo which, at Completion, was or had been used by the Company or which is subsequently used by the Company;

 

  (f) at any time during a period of two years beginning with the Completion Date, solicit or entice away from the Company any supplier to the Company who had supplied goods and/or services to the Company at any time during the six months immediately preceding the Completion Date, if that solicitation or enticement causes or would cause such supplier to cease supplying, or materially reduce its supply of, those goods and/or services to the Company.

 

37


15.2 The covenants in this clause 15 are intended for the benefit of the Buyer and the Company and apply to actions carried out by any Covenantor in any capacity, and whether directly or indirectly, on that Covenantor’s own behalf, on behalf of any other person or jointly with any other person.

 

15.3 Each of the covenants in this clause 15 is a separate undertaking by the Covenantor and shall be enforceable by the Buyer separately and independently of its right to enforce any one or more of the other covenants contained in this clause 15. Each of the covenants in this clause 15 is considered fair and reasonable by the parties, but if any restriction is found to be unenforceable, but would be valid if any part of it were deleted or the period or area of application reduced, the restriction shall apply with such modifications as may be necessary to make it valid and enforceable.

 

15.4 The consideration for the undertakings contained in this clause 15 is included in the Purchase Price.

 

15.5 The obligations in this clause 15 shall not apply in respect of nor prevent any Covenantor from properly discharging his duties and/or obligations in respect of any service agreement, contract of employment, contract for services, or consultancy agreement or other appointment or engagement brief particulars of which have been Disclosed or any Covenantor holding shares or otherwise being interested in any company brief particulars of which have been Disclosed or any such company from continuing to operate its business as carried on at the Completion Date.

 

16. T ERMINATION OF THE S HAREHOLDERS A GREEMENT

 

16.1 Notwithstanding any non-contractual oral or written communications between the parties regarding its subject matter and/or anything to the contrary contained in the Shareholders Agreement, the Company and each of the Sellers that is a party to the Shareholders Agreement hereby terminates the Shareholders Agreement with effect from the Completion Date.

 

16.2 With effect from the Completion Date, the Company and each of the Sellers that is a party to the Shareholders Agreement hereby, irrevocably and unconditionally, releases and waives all and any rights, interests, demands and claims of any nature arising on or before the Completion Date and whether or not presently known, including without limitation any and all redemption or pre-emptive rights and/or any other rights that it may have against any other party to the Shareholders Agreement under or pertaining to the Shareholders Agreement.

 

38


17. C ONFIDENTIALITY AND ANNOUNCEMENTS

 

17.1 No Seller shall at any time disclose to any person or use to the detriment of the Company this Agreement or any trade secret or other confidential information which it holds in relation to the Company and its affairs except:

 

  (a) so far as may be required by law, and in such circumstances only after (to the extent permitted by law) prior consultation with the Buyer;

 

  (b) to the extent otherwise expressly permitted by this Agreement;

 

  (c) with the prior consent in writing of the Buyer;

 

  (d) where the confidential information enters the public domain otherwise than as a result of a breach of this clause 17.1.

 

17.2 No party shall make any announcement relating to this Agreement or its subject matter without the prior written approval of the other party except as required by law or by any legal or regulatory authority (in which case the parties shall co-operate, in good faith, in order to agree the content of any such announcement so far as practicable prior to it being made).

 

18. F URTHER ASSURANCE

Each Seller shall during the 12 month period following Completion promptly execute and deliver all such documents, and do all such things, as the Buyer may from time to time reasonably require for the purpose of giving full effect to the provisions of this Agreement and (provided the out of pocket expense thereof is borne by the Buyer or by the Company each Covenantor shall during the 12 months following Completion provide such assistance and information as shall reasonably be requested by the Buyer (having regard to such Covenantor’s role with the Company and expertise) for the purpose of reflecting the acquisition of the Company by the Buyer in the Buyer’s audited financial statements and associated filings.

 

19. A SSIGNMENT

 

19.1 Except as provided otherwise in this Agreement, no party may assign, or grant any Encumbrance or security interest over, any of its rights under this Agreement or any document referred to in it.

 

19.2 Each party that has rights under this Agreement is acting on its own behalf.

 

19.3 The Buyer may require all or any of the Shares to be conveyed at Completion to itself or to any one or more members of its Group and may assign its rights under this Agreement (or any document referred to in this Agreement) but not its obligations to a member of its Group or to any person to whom Shares are transferred, provided always that, to the extent that any such conveyance or assignment increases the liabilities of the Sellers (or any of them) under this Agreement, such increased liability shall not be recoverable against or from the Sellers (or any of them).

 

39


19.4 If there is an assignment:

 

  (a) each Seller may discharge its obligations under this Agreement to the assignor until the Sellers’ Representative receives notice of the assignment;

 

  (b) the assignee may enforce this Agreement as if it were a party to it, but the Buyer shall remain liable for any obligations under this Agreement; and

 

  (c) if the assignee leaves the Buyer’s Group, the Buyer shall procure that all rights assigned are re-assigned to the Buyer or to another member of the Buyer’s Group.

 

20. W HOLE AGREEMENT

This Agreement constitutes the whole agreement between the parties and supersedes and extinguishes all previous drafts, agreements, arrangements and understandings between them, whether written or oral, relating to its subject matter.

 

21. V ARIATION AND WAIVER

 

21.1 Any variation of this Agreement shall be in writing and signed by or on behalf the Buyer and by the Sellers’ Representative.

 

21.2 Any waiver of any right under this Agreement is only effective if it is in writing and it applies only to the party to whom the waiver is addressed and to the circumstances for which it is given and shall not prevent the party who has given the waiver from subsequently relying on the provision it has waived.

 

21.3 The Sellers’ Representative is authorised by the Sellers to enter into any variation of, or grant any waiver in respect of, this Agreement on behalf of all the Sellers.

 

21.4 No failure to exercise or delay in exercising any right or remedy provided under this Agreement or by law constitutes a waiver of such right or remedy or shall prevent any future exercise in whole or in part thereof.

 

21.5 No single or partial exercise of any right or remedy under this Agreement shall preclude or restrict the further exercise of any such right or remedy.

 

21.6 Unless specifically provided otherwise, rights arising under this Agreement are cumulative and do not exclude rights provided by law.

 

40


22. C OSTS

Each party shall pay its own costs in connection with the negotiation, preparation, execution and performance of this Agreement and any documents referred to in it.

 

23. N OTICE

 

23.1 A notice given under this Agreement:

 

  (a) shall be in writing;

 

  (b) shall be sent for the attention of the person, and to the address or fax number, specified in this clause 23 (or such other address, fax number or person as each party may notify to the others in accordance with the provisions of this clause 23);

 

  (c) if given to the Sellers’ Representative shall be deemed to have been given to all the Sellers; and

 

  (d) shall be:

 

  (i) delivered personally; or

 

  (ii) sent by fax; or

 

  (iii) sent by pre-paid first-class post or recorded delivery; or

 

  (iv) (if the notice is to be served by post outside the country from which it is sent) sent by airmail.

 

23.2 The addresses for service of notice are:

 

  (a) The Sellers – Martyn Christopher Davies and copied to Lee Clifford and Tom Brown of the Sellers’ Solicitors

 

  (i) Address – Martyn Christopher Davies: at the address set forth in Schedule 1

 

  (ii) Address – Sellers’ Solicitors: 6 Bennetts Hill, Birmingham, B2 5ST

 

  (iii) fax number: none

 

  (b) The Buyer – Columbia Laboratories, Inc.

 

  (i) address: 4 Liberty Square, Boston, MA 02109, USA

 

  (ii) for the attention of: Chief Executive Officer

 

  (iii) fax number +11-617-482-0618:

 

23.3 A notice is deemed to have been received:

 

  (a) if delivered personally, at the time of delivery; or

 

  (b) in the case of fax, at the time of transmission; or

 

41


  (c) in the case of pre-paid first class post, recorded delivery, five Business days from the date of posting; or

 

  (d) in the case of registered airmail, five Business Days from the date of posting; or

 

  (e) if deemed receipt under the previous paragraphs of this clause 23.3 is not within business hours (meaning 9.00 am to 5.30 pm Monday to Friday on a day that is not a public holiday in the place of receipt), when business next starts in the place of receipt and all references to time are to local time in the place of deemed receipt.

 

23.4 To prove service, it is sufficient to prove that the notice was transmitted by fax (and a confirmatory transmission report received) to the fax number of the party or, in the case of post, that the envelope containing the notice was properly addressed and posted.

 

24. S EVERANCE

 

24.1 If any provision of this Agreement (or part of a provision) is found by any court or administrative body of competent jurisdiction to be invalid, unenforceable or illegal, the other provisions shall remain in force.

 

24.2 If any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, the provision shall apply with whatever modification is necessary to give effect to the commercial intention of the parties.

 

25. A GREEMENT SURVIVES COMPLETION

This Agreement (other than obligations that have already been fully performed) remains in full force after Completion.

 

26. T HIRD PARTY RIGHTS

 

26.1 Subject to clause 26.2, this Agreement and the documents referred to in it are made for the benefit of the parties and their successors and permitted assigns and are not intended to benefit, or be enforceable by, anyone else.

 

26.2 The following provisions are intended to benefit, where it is identified in the relevant clauses, the Company and shall be enforceable by it to the fullest extent permitted by law:

 

  (a) clause 15; and

 

  (b) clause 17.

 

26.3 Each party represents to the other that their respective rights to terminate, rescind or agree any amendment, variation, waiver or settlement under this Agreement are not subject to the consent of any person that is not a party to this Agreement.

 

42


27. S UCCESSORS

The rights and obligations of the Sellers and the Buyer under this Agreement shall continue for the benefit of, and shall be binding on, their respective successors and permitted assigns.

 

28. C OUNTERPARTS

This Agreement may be executed in any number of counterparts, each of which is an original and which together have the same effect as if each party had signed the same document.

 

29. G OVERNING LAW AND JURISDICTION

 

29.1 This Agreement and any disputes or claims arising out of or in connection with its subject matter or formation (including non-contractual disputes and claims) are governed by and construed in accordance with the law of England.

 

29.2 The parties irrevocably agree that the courts of England have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this Agreement or its subject matter or formation (including non-contractual disputes and claims).

 

29.3 Each Seller consents to receive service of legal proceedings at the address specified for such Seller in Schedule 1 or such other address in England and Wales as shall be notified to the Buyer for this purpose pursuant to clause 23.

This Agreement has been executed and delivered by the parties as a deed on the date stated at the beginning of it.

 

43


Schedule 1 Particulars of the Sellers and the Shares

 

44


Schedule 2 Particulars of the Company

 

45


Schedule 3 Completion

 

46


Schedule 4 Warranties

 

47


Schedule 5 Particulars of properties

 

48


Schedule 6 Completion Accounts

 

49


Schedule 7 Further Provisions re Columbia Stock

 

50


Schedule 8 Intellectual Property

 

51


Schedule 9 List of Material Contracts

 

52


Schedule 10 Option Exercise Notice

 

53


SIGNED as a DEED by

/s/ NIKIN PATEL

in the presence of:

Witness’ signature: /s/ TOM BROWN

Name: TOM BROWN

Address: FREETH CARTWRIGHT LLP

                6 BENNETTS HILL

                BIRMINGHAM B2 55T

SIGNED as a DEED by

/s/ MARTYN CHRISTOPHER DAVIES

in the presence of:

Witness’ signature: /s/ TOM BROWN

Name: TOM BROWN

Address: FREETH CARTWRIGHT LLP

                6 BENNETTS HILL

                BIRMINGHAM B2 55T

SIGNED as a DEED by

/s/ CLIVE JONATHAN ROBERTS

in the presence of:

Witness’ signature: /s/ TOM BROWN

Name: TOM BROWN

Address: FREETH CARTWRIGHT LLP

                6 BENNETTS HILL

                BIRMINGHAM B2 55T

SIGNED as a DEED by

/s/ PHILIP MICHAEL WILLIAMS

in the presence of:

Witness’ signature: /s/ TOM BROWN

Name: TOM BROWN

Address: FREETH CARTWRIGHT LLP

                6 BENNETTS HILL

                BIRMINGHAM B2 55T

 

54


SIGNED as a DEED by

/s/ EMMA GAINFORD

in the presence of:

Witness’ signature: /s/ Sarah Moore

Name: SARAH MOORE

Address: Freeth Cartwright LLP

                Cumberland Court

                80 Mount Street

                Nottingham NG1 6HH

SIGNED as a DEED by

/s/ CLAIRE MADDEN-SMITH

in the presence of:

Witness’ signature: /s/ Sarah Moore

Name: SARAH MOORE

Address: Freeth Cartwright LLP

                Cumberland Court

                80 Mount Street

                Nottingham NG1 6HH

SIGNED as a DEED by

/s/ SHEN LUK

in the presence of:

Witness’ signature: /s/ Sarah Moore

Name: SARAH MOORE

Address: Freeth Cartwright LLP

                Cumberland Court

                80 Mount Street

                Nottingham NG1 6HH

SIGNED as a DEED by

/s/ MICHAEL FANFARILLO

in the presence of:

Witness’ signature: /s/ Sarah Moore

Name: SARAH MOORE

Address: Freeth Cartwright LLP

                Cumberland Court

                80 Mount Street

                Nottingham NG1 6HH

 

55


SIGNED as a DEED by

/s/ ROBERT HARRIS

in the presence of:

Witness’ signature: /s/ Sarah Moore

Name: SARAH MOORE

Address: Freeth Cartwright LLP

                Cumberland Court

                80 Mount Street

                Nottingham NG1 6HH

SIGNED as a DEED by

/s/ ANDREW PARKER

acting by his attorney Nikin Patel

in the presence of:

Witness’ signature: /s/ Tom Brown

Name: TOM BROWN

Address: Freeth Cartwright LLP

                6 Bennetts Hill

                Birmingham B2 55T

SIGNED as a DEED by

/s/ STEVE KEMP

in the presence of:

Witness’ signature: /s/ Sarah Moore

Name: SARAH MOORE

Address: Freeth Cartwright LLP

                Cumberland Court

                80 Mount Street

                Nottingham NG1 6HH

 

56


EXECUTED as a DEED by

THE UNIVERSITY OF NOTTINGHAM

acting by:

/s/ Andrew Unitt

(Authorised Signatory)

/s/ Paul Greytrix

(Authorised Signatory)

 

EXECUTED as a DEED by

COLUMBIA LABORATORIES, INC.

acting by

   
    /s/ Frank Condella
    Authorized Officer
in the presence of:    

Witness’ signature: /s/ Ian Fagelson

Name (in block capitals): IAN FAGELSON

Address: Reed Smith LLP

                The Broadgate Tower

                20 Primrose Street

                London EC 2A2RS

 

EXECUTED as a DEED by

MOLECULAR PROFILES LIMITED

acting by

   
    /s/ Nikin Patel
    Director
in the presence of:    

Witness’ signature: /s/ Tom Brown

Name (in block capitals): TOM BROWN

Address: Freeth Cartwright LLP

                6 Bennetts Hill

                Birmingham B2 55T

 

57

Exhibit 10.1

The Secretary of State for Business, Innovation and Skills

Department for Business, Innovation and Skills

1 Victoria Street

London

SW1H 0ET

12 September 2013

Molecular Profiles Ltd Regional Growth Fund Assistance

In consideration of the Secretary of State for Business, Innovation and Skills (the “Secretary of State”) being willing, at our request, to make Molecular Profiles Ltd an offer of up to £1,600,000 (One Million Six Hundred Thousand Pounds) under the terms of the Grant Offer Letter dated 5 September 2013 under reference 01.09.02/1268C or under the terms of any letter relating to the same grant which varies or supersedes that letter (together the “Grant Offer Letter”) Columbia Laboratories Inc hereby undertakes to provide sufficient funds to enable Molecular Profiles Ltd to perform its obligations in accordance with the terms of the Grant Offer Letter.

In this guarantee “Guaranteed Obligations” means all monies, debts and liabilities of any nature (whether actual or contingent) from time to time due, owing or incurred by or from Molecular Profiles Ltd to the Secretary of State under or in connection with the Grant Offer Letter.

Columbia Laboratories Inc guarantees to the Secretary of State that, whenever Molecular Profiles Ltd does not pay any of the Guaranteed Obligations when due, to pay on demand the Guaranteed Obligations.

Columbia Laboratories Inc will make any payments under this guarantee in full, without any deduction or withholdings whatsoever.

Further, Columbia Laboratories Inc agrees that if any payments due from Molecular Profiles Ltd are not recoverable from Columbia Laboratories Inc as guarantor or surety for Molecular Profiles Ltd for any reason whatsoever those payments shall nevertheless be recoverable from Columbia Laboratories Inc as principal debtor and shall be payable by Columbia Laboratories Inc on demand.

Columbia Laboratories Inc as principal debtor and as a separate and independent obligation and liability agrees to indemnify and keep indemnified the Secretary of State in full and on demand from and against all and any losses, costs, claims, liabilities, damages, demands and expenses suffered or incurred by the Secretary of State arising out of, or in connection with, any failure of Molecular Profiles Ltd to perform or discharge any of its obligations or liabilities in respect of the Guaranteed Obligations.

Any amounts due from Columbia Laboratories Inc shall carry interest at 1.5% above the base rate for the time being of the Bank of England or at the European Commission’s reference rate for the United Kingdom as published in the Official Journal from time to time, whichever is the higher, from the date of demand to the date of payment.

The Secretary of State may claim under this guarantee at the same time as or after making demand of Molecular Profiles Ltd or before, at the same time as, or after taking any action to claim under or enforce any other right, security or guarantee which it may hold from time to time in respect of the Guaranteed Obligations.

Columbia Laboratories Inc shall accept a certificate or other document signed by the Secretary of State or on his/her behalf as conclusive evidence of amounts repayable by Molecular Profiles Ltd.

Columbia Laboratories Inc has not received any security from Molecular Profiles Ltd for giving this guarantee and we shall not take any security for its liability under this guarantee for so long as any sums may become

 

Page 1 of 2


repayable under the Grant Offer Letter without first obtaining written consent from the Secretary of State. If, in contravention of that undertaking, Columbia Laboratories Inc takes any security Columbia Laboratories Inc shall hold the security and all or any amounts realised by Columbia Laboratories Inc from it on trust for the Secretary of State.

Columbia Laboratories Inc shall not take any steps to enforce any right or claim against Molecular Profiles Ltd or any co-guarantor in respect of any monies paid by Columbia Laboratories Inc to the Secretary of State pursuant to this guarantee or any other liabilities between Molecular Profiles Ltd and Columbia Laboratories Inc unless and until all of the Guaranteed Obligations owing to the Secretary of State (both actual and contingent) have been performed and discharged in full.

This guarantee is a continuing guarantee and will remain in force until the Guaranteed Obligations have been performed and discharged in full. Columbia Laboratories Inc’s liability under this guarantee will not be affected by: (a) any concession, time, indulgence or release granted by the Secretary of State to Molecular Profiles Ltd or any other person, (b) the Secretary of State’s failure to take, perfect, enforce or hold unimpaired any security, indemnity or guarantee taken for the Guaranteed Obligations (c) any payment or dealing or anything else (whether by or relating to Molecular Profiles Ltd, Columbia Laboratories Inc or any other person) which would, but for this paragraph, operate to discharge or reduce the Guaranteed Obligations or (d) any termination, amendment, variation, novation, replacement or supplement of or to any of the Guaranteed Obligations (including without limitation any change in the purpose of, any increase in or extension of, the Guaranteed Obligations.

This guarantee and any non-contractual obligations arising out of or in connection with it shall be governed by the laws of England. Columbia Laboratories Inc agrees that the courts of England will have jurisdiction to hear and settle any dispute which arises in connection with this guarantee, although this shall not limit the right of the Secretary of State to bring proceedings against Columbia Laboratories Inc in any other court of competent jurisdiction. Columbia Laboratories Inc irrevocably agree only to bring proceedings in the courts of England. Columbia Laboratories Inc agrees in connection with proceedings in England that any writ, judgment or other notice of process shall be sufficiently and effectively served on Columbia Laboratories Inc if delivered to 8 Orchard Place, Nottingham Business Park, Nottingham, NG8 6PX.

This guarantee shall be in addition to any other guarantee for the Guaranteed Obligations under the Grant Offer Letter by Molecular Profiles Ltd signed by Columbia Laboratories Inc that the Secretary of State may hold.

This guarantee shall remain in full force and effect even if Columbia Laboratories Inc or Molecular Profiles Ltd have merged or amalgamated with another company or if Columbia Laboratories Inc or Molecular Profiles Ltd have changed their respective constitutional documents.

Any demand or other communication concerning this guarantee should be sent to Columbia Laboratories Inc at our registered office for the time being.

Signed: .…/s/ Frank Condella…………………………….

Print name: .…Frank Condella…………………………….

Company Director

for and on behalf of:

Columbia Laboratories Inc

 

Page 2 of 2

Exhibit 10.2

THIS EMPLOYMENT AGREEMENT is made this 12 day of September 2013

BETWEEN:

 

(1) MOLECULAR PROFILES LIMITED (company number 3397582) whose registered office is at 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX (“the Company”); and

 

(2) DR. NIKIN PATEL of 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX (“you”).

IT IS AGREED as follows

 

1. DEFINITIONS

 

1.1. In this agreement the following expressions have the meanings set out next to them

 

“the Company”,    MOLECULAR PROFILES LIMITED of 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX.
“you”,    Dr. Nikin Patel.
“Associated Employer”    As defined in the Employment Rights Act 1996.
“the Board”    means the board of directors of the Company for the time being.
“person”    Any individual, firm, partnership, association (whether incorporated or otherwise), private members club, company, corporation, joint venture, trust, organisation or other incorporated or unincorporated body (in each case whether or not having separate legal personality).
“the employment”    your employment under this agreement.
“Inventions”    The matters set out in sub-clause 25.1.
“Intellectual Property”    Patents, trade marks and service marks (whether registered or unregistered), rights in trade or business names, copyrights (including rights in computer software), registered and unregistered designs, design copyrights, design rights and rights in designs and moral rights (whether or not any of these are registered and including applications for registration of any such thing and renewals and extensions of them) capable of subsisting under English law and all rights or forms of protection of a similar nature or having equivalent or similar effect to any of these which may subsist anywhere in the world.


1.2. Words and expressions defined in the Companies Act 2006 will, unless they are otherwise defined in this agreement, or the context otherwise requires, bear the same meaning in this agreement.

 

2. INTERPRETATION

 

2.1 In this agreement, the headings and table of contents are inserted for convenience only and do not affect its interpretation or construction.

 

2.2 In this agreement, references to clauses, sub-clauses and schedules are, unless otherwise stated, to clauses and sub-clauses of and schedules to this agreement. References to this agreement include clauses and sub-clauses of and schedules to this agreement.

 

2.3 In this agreement, unless the context does not so admit, references to the singular include the plural and vice versa.

 

2.4 In this agreement, unless the context does not so admit, references to the masculine, feminine or neuter include each of them.

 

2.5 In this agreement, references to statutes or to statutory instruments include all re-enactments, amendments, extensions or modifications of them and any regulations made under them.

 

2.6 In this agreement ‘writing’ or ‘written’ shall include any means of visible reproduction.

 

3. YOUR EMPLOYMENT

The employment under this agreement commenced on 12 September 2013.

 

4. PERIOD CONTINUOUSLY EMPLOYED

For the purposes of the Employment Rights Act 1996 your period of continuous employment began on 1 October 1998. No employment with a previous employer shall count towards your period of continuous employment with the Company.

 

5. FORMER AGREEMENTS

 

5.1 This agreement supersedes and is in substitution for all previous agreements, whether oral or in writing, express or implied and whether of an employment nature or otherwise, between you and the Company. All subsisting agreements are terminated by mutual consent with immediate effect.

 

6. JOB TITLE AND DESCRIPTION

 

6.1

You will be employed by the Company and shall serve the Company in the position of CEO, Molecular Profiles. In circumstances where you are suspended, whether pursuant to clause 30 of this agreement or otherwise or at any time after either party has served notice to terminate the employment or otherwise purports to do so, the Company may, at its sole and absolute

 

2


  discretion, appoint any other person to carry out your duties and/or exercise any of your powers.

 

6.2 In addition to the duties which the position set out in clause 6.1 normally entails, you shall also carry out such duties as the Company or an Associated Employer may require you to perform from time to time.

 

6.3 The Company may require you, without additional remuneration, to perform such services or to take up any other position than that set out in clause 6.1, including but not limited to any services for or position with an Associated Employer, that the Company considers appropriate provided that any such requirement under this clause 6.3 will not place you in a position in which you would reasonably need to permanently relocate to comply with the requirement.

 

7. PROMOTION AND PROTECTION OF THE EMPLOYER’S INTERESTS

 

7.1 You undertake to the Company and to any Associated Employer that during the employment you will:

 

  7.1.1 faithfully, diligently and competently perform such duties and exercise such powers consistent with them as may be from time to time required of, assigned to or vested in you by the Company;

 

  7.1.2 to obey the reasonable and lawful directions of the Company or directions given under the authority of the Company;

 

  7.1.3 to comply with all rules, regulations, policies, statements and procedures from time to time issued by the Company;

 

  7.1.4 to protect the Company and any Associated Employer from unnecessary or disproportionate risk;

 

  7.1.5 to keep the Company at all times promptly and fully informed (in writing if so requested) of your conduct of the business of the Company or any Associated Employer and to provide such information, explanations, data and assistance in connection with it as the Company may require;

 

  7.1.6 to use your best endeavours to promote and further the interests of the Company and any Associated Employer and to further the trade and business of the Company and any Associated Employer;

 

  7.1.7 subject as hereinafter provided unless prevented by incapacity, illness of injury or with the prior agreement of the Company, devote, during normal working hours and such additional times as provided for at clause 9 below, the whole of your time, attention and skill to your duties and to the furtherance of the business and interests of the Company and any Associated Employer;

 

  7.1.8 undertake such travel both within the United Kingdom and abroad as may be required by the Company from time to time in its sole and absolute discretion;

 

  7.1.9 at all times comply with, abide by and accept the requirements or directions of any regulator;

 

3


  7.1.10 avoid situations where your personal interests conflict with the interests of the Company or any Associated Employer or any of its or their customers and, if you believe that any such conflict of interest may exist, disclose the same to the Company without delay.

 

7.2 You undertake to the Company and to any Associated Employer that during the employment you will not:

 

  7.2.1 do anything which may result in damage being caused to the Company’s interests, trade, business, or goodwill, to bring the Company into disrepute or which is prejudicial to the Company including without limitation making any untrue, misleading or disparaging statement in relation to the Company or any Associated Employer (or any of its or their employees or officers);

 

  7.2.2 without the prior approval of the Board, either as principal, employee or agent carry on or be engaged, concerned or interested either directly or indirectly in any other trade, profession, business or occupation (including any public or private activity) or hold any directorship or other office in any company or other body whether incorporated or unincorporated;

 

  7.2.3 without prejudice to the generality of clause 7.2.2 and without the prior approval of the Board, introduce to any other person business of a kind in which the Company is for the time being engaged or capable of becoming engaged or with which the Company is able to deal in the course of the business for the time being carried on or planned by the Company to be carried on;

 

  7.2.4 without the Company’s prior written permission, have any financial benefit from contracts made by the Company with any person (including but not limited to any supplier to the Company or any Associated Employer);

 

  7.2.5 without the Company’s prior written permission, receive or obtain directly or indirectly any commission, gift or other inducement in respect of any sale or purchase of any goods or services or other business transaction (whether procured by you or by someone else) effected by the Company or on the Company’s behalf;

 

  7.2.6 without the Company’s prior written permission, hold any shares or securities or have any interest of any kind in any company (other than the Company or any Associated Employer) or other business organisation, save that you may hold not more than five per cent of the issued shares or other securities of any class of any one company which is not a competitor of the Company or any Associated Employer, where such shares or other securities are listed or dealt in on a recognised investment exchange in the United Kingdom or elsewhere, and are to be held by you for investment purposes only;

 

  7.2.7 without the Company’s prior written permission take any preparatory steps to join a competitor of the Company or to set up in competition with the Company;

 

  7.2.8 enter on the Company’s behalf and without the Company’s prior written consent into any obligation for the acquisition whether by lease or purchase of any land, building or premises;

 

4


  7.2.9 give or agree to give on the Company’s behalf and without the Company’s prior written consent any debenture, mortgage or charge on any of the Company’s property;

 

  7.2.10 engage or dismiss on the Company’s behalf and without the Company’s prior written consent any employee;

 

  7.2.11 after the termination of the employment represent yourself as being employed by or connected with the Company or any Associated Employer.

 

7.3 If you are in breach of any of the express or implied terms of this agreement you must immediately disclose the breach to the Company and must immediately inform the Company if you become aware of any misconduct or other breach of contract committed by any of the Company’s employees or directors.

 

7.4 To ensure that the Company’s property is not being used for improper purposes, the Company reserves the right to monitor and record all usage of the Company’s telephones, mobile phones, faxes and IT equipment and systems and to monitor incoming and outgoing communications including but not limited to retrieving and reviewing the contents of files, emails, messages and searches that have been made on the internet via the Company’s systems. You hereby give authority for the Company to do so.

 

7.5 You agree to comply with any rules, policies and procedures set out in the Company’s Employee Handbook from time to time. The Employee Handbook does not form part of this agreement and the Company may amend it at any time. To the extent that there is any conflict between the terms of this agreement and the Employee Handbook, the terms of this agreement shall prevail.

 

8. PLACE OF WORK

 

8.1 Your principal place of work will be 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire NG8 6PX.

 

8.2 The Company may, however, require you to work at other locations (including overseas) in the performance of your duties provided that you may not without your agreement be required to work overseas for any consecutive period of more than four weeks.

 

9. NORMAL HOURS OF WORK

 

9.1 Your normal hours of work 37.5 hours per week Monday to Friday.

 

9.2 You will also be required to work such additional hours as may be necessary for the performance of your duties.

 

9.3 Due to the autonomous nature of your role the duration of working time cannot be measured or monitored and, accordingly your employment falls within the scope of regulation 20 of the Working Time Regulations 1998.

 

10. REMUNERATION

 

10.1 During the employment the Company will pay you a basic salary at the rate £183,266 per annum (the “ Base Salary ”).

 

5


10.2 You will receive no additional pay for hours worked in excess of your normal hours of work.

 

10.3 Your salary will accrue from day to day but will not accrue on any day during which you are absent due to sickness or injury or for some other unauthorized reason.

 

10.4 Your salary will be payable in equal monthly installments in arrears on or around the 28th day of each month or on such other day as may be notified to you by the Company from time to time.

 

10.5 Payment will be made by direct bank transfer and will be subject to such deductions as the Company may make for income tax, employee’s National Insurance contribution and any other taxes, social security contributions and withholdings as the Company may deduct.

 

10.6 Your salary shall be inclusive of any fees to which you may be entitled as a director or secretary of the Company or any Associated Employer if appointed as such.

 

11. DISCRETIONARY BONUS

 

11.1 You may at the Company’s sole and absolute discretion be paid a bonus in accordance with this clause 11 and the Company’s discretionary bonus scheme in place from time to time. In considering any such bonus, the Company will, amongst other factors, consider your and the Company’s performance. If, in the absolute discretion of the Company, you meet the annual performance targets set for you and the Company has hit its targets, such bonus is likely to be 70% of your Base Salary. Such bonus may be greater than 70% of your Base Salary in circumstances where the Company considers, at its absolute discretion, that you have materially exceeded your annual performance targets. Any such bonus (if any) will never exceed 105% of your Base Salary. Any such bonus may be paid to you at such intervals and subject to such conditions as the Company may in its sole and absolute discretion determine. The Company may in its sole and absolute discretion determine whether any such bonus is paid in cash or in some other form.

 

11.2 You will not be eligible for any bonus, or if a bonus has already been awarded but not paid, will not receive payment of any such bonus, if, on the date that bonuses are due to be paid, you are no longer employed by the Company or either you or the Company has served notice to terminate the employment.

 

11.3 If you receive any bonus or payment thereof under this clause 11 or otherwise, the receipt of the same shall not entitle you to receive any further bonus or payments thereof. You acknowledge and agree than any bonuses or payments thereof that you may receive under this clause 11 or otherwise shall be purely discretionary and shall not form part of your contractual remuneration and shall not be pensionable.

 

11.4 The Company may, in its absolute discretion, suspend or discontinue any bonus or the payment thereof at any time in relation to any person or persons, including you. The Company may, in its absolute discretion, impose, vary or remove any conditions in relation to any bonus or the payment thereof at any time, including but not limited to after the award of any bonus or any payment thereof, whether in whole or in part.

 

6


11.5 If the employment or this agreement is terminated for any reason, whether lawfully or unlawfully, you agree that you will not be entitled by way of compensation for breach of contract, unfair dismissal or otherwise to any sum, or other benefit to compensate you for the loss or diminution in value of any actual or prospective rights, benefits or expectations under or in relation to the Company’s discretionary bonus scheme.

 

12. PENSIONS AND BENEFITS

 

12.1 The Company operates a Group Flexible Retirement Plan which you are eligible to join. This is a Company based pension plan. The plan is a 6% pension scheme whereby you are entitled to a 3% contribution (of gross annual salary) from the Company into a Standard Life Scheme, when you make a contribution of 3% or more.

 

12.2 The Company reserves the right to change the provider of the pension scheme, vary the rules and/or terms of the pension scheme and to withdraw any such pension scheme at any time at the Company’s sole and absolute discretion and without paying compensation to you.

 

12.3 Any benefits arising under or in respect of any such pension scheme will be payable by or under the authority of its trustees and the Company neither guarantees nor warrants any such payment.

 

12.4 You may participate in such benefits and benefit schemes as the Company may provide to employees of your seniority and status from time to time, if any, subject in all cases to the terms of the governing documents and policies in force from time to time. Your eligibility to participate in any such benefits and/or benefit schemes shall be subject to you meeting the relevant insurance provider’s eligibility criteria. The Company shall be entitled to change the provider of any benefits and/or benefit schemes, withdraw any such benefits and/or benefit schemes that may be provided from time to time and/or to amend the terms on which any benefit is and/or benefit schemes are provided without paying you any compensation. You acknowledge that as any benefits and/or benefit schemes that may be provided are insured arrangements, the payment and/or provision of any benefits whatsoever is subject to the discretion of the insurers and subject to the terms and conditions of the respective benefit and/or benefit scheme. The Company has no obligation to assist you in the advancement of any claim you may make, nor any obligation to make any payment to you should the insurer refuse to pay or provide any or all benefits whatsoever for whatever reason.

 

13. CONTRACTING-OUT CERTIFICATE

 

13.1 There is no contracting-out certificate in force in relation to the employment.

 

14. EXPENSES

 

14.1 The Company will reimburse you for all out of pocket expenses reasonably incurred in the proper performance of the Company’s duties.

 

14.2

Your entitlement to reimbursement in accordance with clause 14.1 above is conditional upon you providing the Company with such invoices, vouchers or other evidence as may be required by the Company and subject to you complying with such guidelines or regulations as

 

7


  the Company may from time to time issue in relation to the incurring and reimbursement of expenses.

 

15. HOLIDAYS

 

15.1 The Company’s holiday year is from 1 st  January until 31 st  December each year.

 

15.2 You are entitled to eight public and Bank holidays which are New Year’s Day, Good Friday, Easter Monday, May Day, Spring Bank Holiday, Late Summer Bank Holiday, Christmas Day and Boxing Day.

 

15.3 In addition, you are entitled to 26 days paid holiday each holiday year. Where you are employed for only part of a holiday year, either on commencement or termination of the employment, you will be entitled to a pro-rated holiday entitlement based on the number of complete months worked in that holiday year.

 

15.4 All holiday is to be taken on days that are convenient to the Company, which are approved by the Company in writing.

 

15.5 You shall be entitled to carry forward up to 3 days’ holiday from any holiday year to the next holiday year with the prior written approval of the Company provided any such holiday carried forward is taken by 31 March in the next holiday year. No payment will be made for any holiday accrued but not taken in a holiday year or carried forward in accordance with this clause save in the year in which the employment terminates (see clause 15.6 below).

 

15.6 Upon termination of the employment, you will be entitled to a payment of one day’s salary (calculated at a daily rate of 1/260ths of your annual basic salary) for each complete day of accrued but unused holiday entitlement at such termination but if at the termination date you have taken holiday in excess of your accrued holiday entitlement at that date, the Company will make a commensurate deduction from any salary payment (whether of salary, expenses or otherwise) to be made to you.

 

15.7 If notice is served to terminate the employment by either party the Company may require that unused holiday entitlement which has accrued or will accrue prior to the date of termination be taken during the notice period. Any statutory holiday entitlement will be deemed to be taken before any contractual holiday entitlement.

 

16. ABSENCE FROM WORK

 

16.1 If you are absent from work for any reason and the absence has not previously been authorised by the Company you must notify the Company orally or in writing as soon as possible and in any event by 9.30 a.m. on the first day of absence and from then on you must keep the Company informed of your circumstances and your anticipated return to work. If you notify the Company orally, you must confirm the reasons for your absence in writing as soon as practicable.

 

16.2 You must report to the Company on the first day that you return to work after a period of absence for which you did not obtain approval prior to the absence from the Company. You will be required to state the dates of and reasons for your absence and will be provided with a form for that purpose.

 

8


16.3 If you are absent from work due to sickness or injury and your absence continues for more than seven days, you must provide a doctor’s certificate on the eighth day of absence. You must then provide a doctor’s certificate weekly.

 

17. INCAPACITY PAY

 

17.1 If you are absent from work due to sickness or injury and comply with the requirements set out in this clause and clause 16, you will receive your salary at full rate for a maximum period of 3 months and thereafter two thirds of your salary for a maximum period of 3 months and thereafter half of your salary for a maximum period of 6 months of absence in aggregate in any period of 52 consecutive weeks. Any such payments are inclusive of any statutory sick pay entitlement. Any payment which the Company makes under this clause 17.1 may be varied or discontinued at any time at the Company’s sole and absolute discretion.

 

17.2 If your absence is or appears to be occasioned by the negligence, nuisance or breach of statutory duty by or on behalf of any person in respect of which compensation is or may be recoverable by you then all incapacity payments made by the Company will constitute loans to you. You must notify the Company immediately of any relevant circumstances, claim, compromise, settlement or judgment made or awarded in connection therewith and must give the Company all particulars of such matters as the Company may reasonably require. You must use all reasonable endeavours to recover (by way of settlement or otherwise) damages for loss of earnings over any period for which salary has been paid or shall be paid to you, keeping the Company informed of the commencement, progress and outcome of any such claim. If the Company so requires you must repay to the Company a sum as the Company may determine not exceeding:

 

  17.2.1 the amount of compensation recovered by you under such claim, compromise, settlement or judgment in respect of lost earnings; or

 

  17.2.2 the aggregate incapacity pay which you received from the Company less an amount equivalent to any statutory sick pay which the Company was obliged by law to pay to you.

 

17.3 Your eligibility to receive incapacity pay and/or statutory sick pay (see clause 18 below), or your receipt of any of the same, shall not affect the Company’s ability to terminate the employment and/or this agreement.

 

18. STATUTORY SICK PAY

 

18.1 The Company operates the statutory sick pay scheme. You must co-operate in the maintenance of all necessary records. Any payment made to you during a period of sickness or injury will satisfy (or contribute to if it does not satisfy) any liability of the Company to make payment under the statutory sick pay scheme. For the purposes of the statutory sick pay scheme, your “qualifying days” are Monday to Friday.

 

19. MATERNITY AND PARENTAL LEAVE

 

19.1 Your maternity, paternity and adoption leave and pay rights are according to statute.

 

19.2 Your parental leave rights are according to statute.

 

9


20. COLLECTIVE AGREEMENTS

There are no collective agreements currently in force which directly or indirectly affect the employment.

 

21. RIGHT TO REQUIRE A MEDICAL EXAMINATION

 

21.1 The Company may in its sole and absolute discretion require you to provide evidence, satisfactory to the Company, of any sickness or injury suffered by you and/or provide the Company with medical evidence of your fitness to return to work after any period of absence from work due to sickness or injury.

 

21.2 You must upon the Company’s request and at the Company’s expense undergo a medical examination by any registered medical practitioner nominated by the Company and, for the purposes of the Data Protection Act 1998 and any other applicable legislation:

 

  21.2.1 you agree to give consent to such examination; and

 

  21.2.2 you agree to give consent that a report may be published in relation to the examination and that the Company may have access to it.

 

22. RIGHT TO SEARCH

The Company reserves the right to make searches of your person and personal property whilst on the Company’s premises or any premises from which the Company or any Associated Employer operates without prior notice provided that any such search is carried out in the presence of at least two witnesses. Any personal search will be conducted by persons of the same sex as you. Personal property includes any vehicle owned by the Company.

 

23. HEALTH AND SAFETY

 

23.1 You should be familiar with the Company’s health and safety policy and all procedures concerning safety in emergencies including the use and operation of safety equipment and protective clothing.

 

23.2 A copy of the Company’s health and safety policy can be obtained from the Company upon request.

 

23.3 Details of any accident must be reported as soon as possible after the event.

 

24. CONFIDENTIAL INFORMATION

 

24.1 The provisions of this clause 24 apply to you for the benefit of the Company and any Associated Employer.

 

24.2 You acknowledge that in the course of the employment you will have access to and be entrusted with information in respect of the business of the Company and/or any Associated Employer and the Company’s and/or any Associated Employer’s customers’ businesses, which information is or may be secret or confidential and important to the Company, any Associated Employers and the Company’s customers respectively (“Confidential Information”).

 

10


24.3 Confidential Information includes (but is not limited to):

 

  24.3.1 trade secret or confidential or secret information concerning the business development, affairs, future plans, proposals, inventions, ideas, transactions, business methods, connections, operations, accounts, finances, organisation, processes, policies or practices, statements, rules, regulations, designs, products, machinery, manufacturing processes, dealings, trading, software, or know-how relating to or belonging to the Company and/or to any Associated Employer or any of its or their suppliers, agents, distributors, clients or customers;

 

  24.3.2 confidential computer software, computer-related know-how, passwords, computer programmes, specifications, object codes, source codes, network designs, business processes, business logic, inventions, improvements and /or modifications relating to or belonging to the Company and/or any Associated Employer;

 

  24.3.3 details of the Company’s or any Associated Employer’s financial projections or projects, prices or pricing strategy, advertising, marketing or development plans, product development plans or strategies, fee levels, commissions and commission structures, market share and pricing statistics, marketing surveys and research reports and their interpretation;

 

  24.3.4 confidential research, report or development undertaken by or for the Company or any Associated Employer;

 

  24.3.5 details of relationships or arrangements with, or knowledge of the needs or the requirements of, the Company’s and/or any Associated Employer’s actual or potential clients or customers;

 

  24.3.6 information supplied in confidence by customers, clients or any third party to which the Company or any Associated Employer owes an obligation of confidentiality;

 

  24.3.7 lists and details of contracts with the Company’s or any Associated Employer’s actual or potential suppliers;

 

  24.3.8 details of or information regarding the Company’s or any Associated Employer’s terms of business with customers and suppliers;

 

  24.3.9 details of or information regarding the Company’s or other Associated Employer’s development or staffing plans;

 

  24.3.10 information of a personal or otherwise of a confidential nature relating to fellow employees, directors or officers of and/or consultants to, the Company and/or any Associated Employer for which you may from time to time provide services;

 

  24.3.11 confidential information concerning, or details of, any competitive business pitches, and/or target details;

 

  24.3.12 details of or information regarding the nature and origin of any goods and/or services provided, marketed or sold, obtained or brokered by the Company or any Associated Employer;

 

11


  24.3.13 details of or information regarding the Company’s and/or any Associated Employer’s sales techniques, price lists, pricing policies and/or discount structures;

 

  24.3.14 documents or information marked as confidential on its face; and/or

 

  24.3.15 documents or information which have been given to the Company or any Associated Employer in confidence by any customer, supplier or other person and/or any documents or information which have been supplied to you in confidence or which you have been informed are confidential or which you might reasonably be aware is confidential.

 

24.4 You must not at any time whether during or after the termination of the employment directly or indirectly, whether on your own account or for or on behalf of any other person other than in the proper performance of your duties, with the prior written consent of the Company or as required or permitted by law:

 

  24.4.1 divulge Confidential Information to any person;

 

  24.4.2 use or attempt to use Confidential Information for your own purposes or for any purposes which are not the Company’s or any Associated Employer’s purposes or in any manner which may injure or cause loss either directly or indirectly to the Company or any Associated Employer or its of their business or may be likely to do so; or

 

  24.4.3 through any failure to exercise reasonable care and diligence, cause or bring about any unauthorised disclose or any Confidential Information.

 

24.5 You undertake to use reasonable endeavours to prevent the disclosure of any Confidential Information and keep with complete secrecy all Confidential Information entrusted to you.

 

24.6 Clauses 24.4 and 24.5 do not relate to information that is or may become (other than through your breach of this clause) generally available to the public or which constitutes a protected disclosure within the meaning of section 43A of the Employment Rights Act 1996.

 

24.7 You undertake to promptly disclose to the Company any information which comes into your possession which affects adversely or may affect adversely the Company, any Associated Employer or the business of the Company or any Associated Employer. Such information shall include (but shall not be limited to)-

 

  24.7.1 the plans of any employee to leave the Company (whether alone or in concert with other employees);

 

  24.7.2 the plans of any employee (whether alone or in concert with other employees) to join a competitor or to establish or operate a business in competition with the Company;

 

  24.7.3 any steps taken by any employee to implement either of such plans;

 

  24.7.4 the misuse by any employee of any Confidential Information belonging to the Company or any Associated Employer.

 

12


25. INTELLECTUAL PROPERTY

 

25.1 In this clause “Client” means any client or customer (including any potential client or customer) of the Company and/or any Associated Employer.

 

25.2 You acknowledge that in the course of your employment and as part of your duties both prior to the date of this agreement and following the commencement of this agreement:

 

  25.2.1 you have conceived, originated, made or acquired and may conceive, originate, make or acquire individually or with others, certain inventions processes, formulas, utility models, novel creations, ideas, discoveries, know how, trade secrets, business names, developments, writings, trade marks, service marks, designs, drawings, improvements and innovations, whether or not capable of being patented or registered in some other way; and

 

  25.2.2 you have developed or produced and may develop or produce, individually or with others, certain works in which copyright, design right and/or database right will subsist in various media, including but not limited to electronic materials (including but not limited to software or instruction manuals),

(together called “Inventions”).

 

25.3 You undertake to promptly following the date of this agreement disclose to the Company in writing full particulars of any Inventions created prior to the date of this agreement and you undertake to disclose to the Company in writing full particulars of any Inventions created after the date of this agreement promptly following their creation. You undertake not to use, disclose to any other person or exploit any Inventions without the Company’s prior written consent.

 

25.4 You acknowledge that any and all Inventions and the Intellectual Property subsisting or which may in the future subsist in any Inventions, including but not limited to any that:

 

  25.4.1 relate or related in any manner to the business of the Company or any Associated Employer or to the Company’s or any Associated Employer’s actual or anticipated activities or to any Client or to any Client’s actual or anticipated activities; or

 

  25.4.2 involve or involved the use of the Company’s, any Associated Employer’s or any Client’s equipment, supplies, facilities, confidential information, Intellectual Property or time,

hereby vest in or be or will, on creation, subject to the provisions of the Patents Act 1977, the Registered Designs Act 1949 and the Copyright Designs and Patents Act 1988, vest in and be the Company’s (or if required by the Company, the relevant Client’s) exclusive property in the United Kingdom or any other part of the world as absolute beneficial owner without any payment to you for it and where the same does not automatically vest in accordance with this clause, you hereby irrevocably and unconditionally assign the same to the Company (or if required by the Company, the relevant Client).

 

25.5

You agree to assist the Company and, if requested by the Company, any Client in connection with any application in relation to Inventions and to prepare and execute such instruments and do all such other acts and things as may be necessary or desirable to enable the Company, the

 

13


  relevant Client or their respective nominees to obtain and maintain protection of any Inventions vested in the Company or the relevant Client in such parts of the world as may be specified by the Company, the relevant Client or their respective nominees and to enable the Company or the relevant Client to exploit any Inventions vested in them to the best advantage.

 

25.6 You hereby irrevocably appoint the Company to be your attorney in your name and on your behalf to do all such acts and things and to sign all such deeds and documents and to use your name for the purpose of giving the Company, any relevant Client or their respective nominees the full benefit of this clause 25. You agree that, as evidence to any person, a certificate signed by the Company or by any duly authorised employee that any act or thing or deed or document falls within the authority hereby conferred by this clause 25.6 will be conclusive evidence that this is the case.

 

25.7 You agree that any and all Inventions disclosed by you to any person, published or described in a patent or registered design application or registered trade mark or service mark application filed by you (alone or jointly) or on your behalf within 12 months after the termination of this agreement will be presumed to have been conceived, made, developed or produced by you in the course of the employment unless proved by you to have been conceived, made, developed or produced by you after the termination of this agreement.

 

25.8 You irrevocably and unconditionally waive any and all rights which you may have which are or have been conferred on you by Chapter IV of Part 1 of the Copyright, Designs and Patents Act 1988 headed “Moral Rights” and by any other laws of a similar or equivalent nature in any of the countries of the world.

 

25.9 Where an injunction restraining use or exploitation by the Company or any Client of any invention is, in the opinion of the Company’s legal advisers, likely to be granted by a court to a third party, you must do all such acts and things either to render them non-infringing without affecting any of your other duties and obligations under this agreement or shall obtain a licence from the third party granting the Company or the Client as the case may be the right to continue using them.

 

25.10 You must not knowingly do, permit or suffer to be done any act or thing or omit to do any act or thing which might jeopardize or prejudice any of the rights conferred on or vested in the Company or any Client by virtue of this clause or any document signed executed and delivered pursuant to this clause or which might invalidate or prejudice any application made by the Company or any Client for a patent, registered design, copyright, design right or other similar right in any part of the world.

 

25.11 Your obligations under this clause 25 shall continue to apply after the termination of the employment (whether terminated lawfully or not). Each of these obligations is enforceable independently of each of the others and its validity shall not be affected if any of the others are unenforceable to any extent.

 

26. GRIEVANCE PROCEDURE

 

26.1 If you have a grievance relating to the employment, this should be raised initially with your Manager. You may be required to put any such grievance in writing.

 

14


26.2 Your Manager or another appropriate person will consider the grievance and will notify you of its decision.

 

26.3 The grievance procedure in the Employee Handbook shall not apply to the employment.

 

27. DISCIPLINARY PROCEDURE

 

27.1 The Company’s Disciplinary Procedure can be found in the Handbook. The Disciplinary Procedure may be varied, disapplied, removed, added to or supplemented by the Company at any time in its sole and absolute discretion and shall not have contractual effect.

 

28. TERMINATION

 

28.1 Without prejudice to any other term of this agreement providing for earlier termination, the employment may be terminated by either you or the Company giving to the other not less than 6 months’ prior written notice.

 

28.2 The Company may (without prejudice to and in addition to any other remedy) forthwith terminate the employment without prior notice or payment in lieu thereof if, in the opinion of the Company, it appears that you:

 

  28.2.1 are guilty of gross misconduct;

 

  28.2.2 have committed any act of fraud or dishonesty;

 

  28.2.3 have committed any act, which in the opinion of the Company, constitutes a breach (or may have been calculated by you to constitute a breach) of the relationship of trust and confidence between the Company by you;

 

  28.2.4 have misconducted yourself during or outside the course of the employment in a manner, which in the opinion of the Company, brings the Company and/or any Associated Employer into disrepute or otherwise harms or has the potential to harm the interests of the Company and/or any Associated Employer or its or their business(es), including (without prejudice to the generality of foregoing), any conduct in respect of which disciplinary and/or corrective proceedings and/or measures are brought or implemented (or might be brought or implemented) by any public body, regulatory authority or society that is relevant to the Company and/or any Associated Employer and/or the employment;

 

  28.2.5 have committed any, serious and/or any repeated, breach of or failure to observe, any of the terms, conditions or stipulations contained in this agreement;

 

  28.2.6 are guilty of serious and/or any repeated negligence or incompetence;

 

  28.2.7 have committed any breach of any of the rules, regulations, codes of practice, recommendations and/or requirements of any public body, regulatory authority or society that is relevant to the Company and/or any Associated Employer and/or the employment;

 

  28.2.8 have provided any misleading or inaccurate information to any public body, regulatory authority or society that is relevant to the Company and/or any Associated Employer and/or the employment;

 

15


  28.2.9 do not possess, have lost or do not obtain any certificate, approval, authorisation, permission, visa, registration, security clearance or any other item that is granted by any third party (included but not limited to any public body, regulatory authority or society) that is necessary or desirable for you to possess for the performance of your duties hereunder;

 

  28.2.10 have become bankrupt or applied for a receiving order or have a receiving order made against you or have entered into any arrangement or composition with your creditors;

 

  28.2.11 have been prohibited by law from acting as a director of any company;

 

  28.2.12 have become of unsound mind or a patient within the meaning of any United Kingdom statute relating to mental health; and/or

 

  28.2.13 have been convicted of any criminal offence (other than an offence under the Road Traffic Acts for which a penalty of imprisonment is not imposed),

and any delay by the Company in exercising such right to terminate shall not constitute a waiver thereof.

 

28.3 Upon the termination of this agreement under clause 28.2, you shall be paid your salary accrued to the date of termination, together with any entitlement to be paid for accrued but untaken statutory holidays at the date of termination but you shall not be entitled to any other payment or compensation whatsoever in respect of such termination.

 

28.4 On the termination of the employment for any reason and howsoever arising:

 

  28.4.1 you shall at the request of the Company, resign from all offices held by you, if any, in or as the representative or nominee of the Company or any Associated Employer, including but not limited to any appointment as director or company secretary of the same; and

 

  28.4.2 you shall, without payment, transfer to the company, or as the Company may otherwise direct, any qualifying shares held by you on behalf of or as the representative or nominee of the Company or any Associated Employer,

and you hereby, irrevocably appoint the Company to be your attorney in your name and on your behalf to sign, execute or do any instrument or act and generally to use your name for the purpose of giving to the Company or its nominee the full benefit of the provisions of this clause 28.4.

 

28.5 After the termination of the employment under this agreement, you shall, on request, render such assistance and perform such tasks and functions as the Company may reasonably require for its business to assist the Company (to deal properly, efficiently and cost-effectively with any matters in connection with the affairs of the Company and/or any Associated Employer and in respect of which you have particular knowledge and expertise by reason of the employment. You shall be entitled to be paid a reasonable fee (not exceeding your base salary pro-rata on termination of this employment) and to be reimbursed all reasonable out of pocket expenses properly incurred in rendering such assistance and performing such tasks and functions.

 

16


29. PAYMENT IN LIEU OF NOTICE

 

29.1 Whether or not notice is served by the Company or you to terminate the employment or if either you or the Company otherwise purports to terminate the employment, the Company may in its sole and absolute discretion elect to terminate the employment at any time and with immediate effect by:

 

  29.1.1 notifying you that the Company is exercising its right under this agreement to make a payment in lieu of notice; and

 

  29.1.2 within 28 days of the notification referred to in clause 29.1.1 above, making to you a payment in lieu of notice in accordance with clause 29.2 below.

 

29.2 When making a payment in lieu of notice pursuant to clause 29.1 above, or otherwise, the Company may make a payment equivalent to your basic salary (as at the date of the termination) only for the whole of the notice period (or, if applicable, its remainder):

 

  29.2.1 in a lump sum; or

 

  29.2.2 in installments over the period until the expiry, if it had been served (in full or at all), of the notice period,

and, in each case, such payments will be subject to income tax and national insurance contributions.

 

29.3 The Company will not be deemed to have made an election to pay in lieu of notice unless written notice to that effect is given to you in accordance with clause 29.1.1. For the avoidance of doubt, the Company’s right to elect to make a payment in lieu of notice does not give you any right to receive one.

 

30. SUSPENSION, CHANGE OF DUTIES AND GARDEN LEAVE

 

30.1 The Company may suspend all or any of your duties and powers or assign you such alternative duties as the Company may in its sole and absolute discretion deem appropriate for such periods and on such terms as it considers expedient in its sole and absolute discretion:

 

  30.1.1 during any period in which the Company is carrying out an investigation into any alleged acts or defaults by you;

 

  30.1.2 in circumstances where it is suspected that you are in breach of any legal or regulatory requirement, including but not limited to any such requirements imposed by any public body, regulatory authority or society that is relevant to the Company and/or any Associated Employer and/or the employment and/or any stock exchange on which the Company’s or any Associated Employer’s shares are traded,

and during any such period, you shall continue to receive your salary and contractual benefits.

 

30.2 At any stage during your notice period (whether notice is given by you or by the Company) or if you seek to or indicate an intention to resign as an employee of the Company or any Associated Employer or to terminate the employment without notice the Company may, in its sole and absolute discretion (without any requirement to give a reason):

 

17


  30.2.1 alter your duties to such other duties as the Company may determine in its sole and absolute discretion, including but not limited to non-client facing duties; or

 

  30.2.2 instruct you to remain away from work on garden leave (“Garden Leave”).

 

30.3 During any period of Garden Leave;

 

  30.3.1 You may be excluded from all or any premises of the Company or any Associated Employer;

 

  30.3.2 you must be available for work but the Company is not obliged to provide you with any work and may require you to perform different duties and/or tasks from your normal duties;

 

  30.3.3 the Company shall be entitled to require you to perform work at home in relation to matters of which you have knowledge or which fall within your competence;

 

  30.3.4 you will be entitled to receive your salary and any contractual benefits under this agreement, excluding any bonus of any nature, which you will not be entitled to in respect of any period of Garden Leave;

 

  30.3.5 you may not, without the prior written consent of the Company, contact or attempt to contact any client, customer, prospective client or customer, agent, professional adviser, employee, consultant, supplier or broker of the Company or any Associated Employer;

 

  30.3.6 you will not be permitted to work for any other organisation or on your own behalf without the Company’s prior written consent;

 

  30.3.7 you shall keep the Company informed of your whereabouts (except in any period taken as holiday) so that you can be called upon to perform any appropriate duties as requested by the Company (and if required to provide the Company with a contact telephone number and email address for this purpose);

 

  30.3.8 you shall refer to the Company immediately any communications in whatever form received by you from any client or customer or prospective client or customer of the Company or any Associated Employer;

 

  30.3.9 you must take any accrued and accruing holiday (and any accrued but unused holiday entitlement shall be deemed to be taken during any period of Garden Leave) and this clause 30.3.9 is notice to you pursuant to Regulation 15(3) of the Working Time Regulations 1998 that holiday is to be taken during this period;

 

  30.3.10 you may be required to return to the Company all documents and items of property which belong to the Company or any Associated Employer (including but not limited to those which contain or refer to any Confidential Information (as defined in clause 24)) and which are in your possession or under your power or control;

 

18


  30.3.11 you must immediately on request resign as a director, secretary or from any other appointment held in or on behalf of the Company or any Associated Employer without claim for compensation for loss of office (and in the event of your failure to do so the Company is hereby irrevocably appointed to appoint some person in your name and on your behalf to sign and deliver such resignation(s) to the Company);

 

  30.3.12 all other terms and conditions of the employment (both express and implied) will remain in full force and effect; and

 

  30.3.13 you will continue to owe the Company a duty of fidelity and good faith and, if applicable, duties as a fiduciary, in full and to the same extent as existed prior to the Garden Leave period.

 

31. RECONSTRUCTION

If the employment is terminated by reason of the Company’s liquidation for the purposes of an amalgamation or reconstruction and you are offered work by any person resulting from such amalgamation or reconstruction on terms no less favourable than the terms of this agreement you will have no claim against the Company in respect of the termination of the employment.

 

32. DEDUCTIONS

You hereby irrevocably agree that the Company may at any time deduct any sum you owe to the Company or any Associated Employer (including without limitation any overpayment of salary or other benefits) from any sum the Company owes to you.

 

33. COMPANY DOCUMENTS

All notes, memoranda, records, lists of customers and suppliers and employees, papers, documents, correspondence, writings, accounts, designs, price lists, specifications, Company letterhead paper, stationary, computer software, computer programmes, computer operating systems, computers, laptop computers, table computers, mobile phones, PDAs, smart phones, portable devices, material and all information recorded on magnetic tape or disc or otherwise recorded or stored for reproduction whether by mechanical or electronic means including any copy which is from time to time in your possession or control and which relates to the Company or any Associated Employer will be and remain at all times the property of the Company or any Associated Employer (as the case may be). Upon the termination of the employment, or at any other time as requested by the Company, you must return all such items and information in your possession or under your control and will provide to the Company on request a statement that you have complied with these requirements.

 

34. POST TERMINATION COVENANTS

 

34.1 For the purpose of this clause 34 the following expressions have the following meanings respectively-

 

19


  34.1.1 Confidential Information ” has the meaning given to that expression in clause 24;

 

  34.1.2 Customer ” means any person, company or other entity who or which at any time in the 12 months immediately preceding the Termination Date was a customer or client of the Company or any Associated Employer and:

 

  34.1.2.1 with whom or which, during such period you had business dealings in the course of the employment; or

 

  34.1.2.2 in relation to whom or which, you, by reason of the employment, are in possession of any trade secrets or Confidential Information;

 

  34.1.3 Prospective Customer ” means any person, company or other entity with whom or which at any time in the 12 months immediately preceding the Termination Date the Company or any Associated Employer shall have had negotiations or discussions for the supply or provision of goods and/or services supplied and/or provided by the Company or any Associated Employer, and:

 

  34.1.3.1 with whom or which, during such period you had business dealings during the course of those negotiations or discussions; or

 

  34.1.3.2 in relation to whom or which, you, by reason of the employment, are in possession of any trade secrets or Confidential Information;

 

  34.1.4 Relevant Person ” means any person who at any time in the 12 months immediately preceding the Termination Date was employed or engaged by the Company or any Associated Employer:

 

  34.1.4.1 as a vice president, officer, director, and/or senior manager;

 

  34.1.4.2 who has acquired influence over any Customers and/or Prospective Customers by reason of being or having been employed or engaged by the Company and/or any Associated Employer; and/or

 

  34.1.4.3 who is in possession of any trade secrets or Confidential Information relating to the business of the Company or any Associated Employer or relating to any Customer and/or Prospective Customer by reason of being or having been employed or engaged by the Company and/or any Associated Employer;

and with whom you had dealings at any time in the 12 months immediately preceding the Termination Date;

 

  34.1.5 Restricted Business ” means the business of the Company and the business of any Associated Employer (and in each case, any parts thereof) with which you were materially concerned and/or for which you were responsible, in each case at any time during the 12 months immediately preceding the Termination Date;

 

  34.1.6 Restricted Period ” means:

 

  34.1.6.1 in the case of clause 34.2.1 to 34.2.9 the period of 12 months following the Termination Date, less any period of time spent by you on Garden Leave;

 

20


  34.1.6.2 in the case of clause 34.2.10, the whole of the period following the Termination Date;

 

  34.1.7 Supplier ” means any person, company or other entity who or which at any time in the 12 months immediately preceding the Termination Date was a supplier of goods and/or services to the Company or any Associated Employer, and:

 

  34.1.7.1 with whom or which, during such period you had business dealings in the course of the employment; or

 

  34.1.7.2 in relation to whom or which, you, by reason of the employment with the Company, are in possession of any trade secrets or Confidential Information; and

 

  34.1.8 “Termination Date” means the date of termination of the employment, howsoever arising.

 

34.2 You hereby undertake with the Company (for itself and as trustee and agent for each Associated Employer) that you will not without the prior written consent of the Company for the relevant Restricted Period, whether on your own account, or for, with or through any other person company or other entity, directly or indirectly:

 

  34.2.1 carry on or be employed, engaged, interested or concerned in any capacity in any trade or business or occupation whatsoever which is or might reasonably be considered to be in competition with the Restricted Business;

 

  34.2.2 in competition with the Restricted Business solicit, interfere with or entice away or endeavour to solicit, interfere with or entice away any Customer;

 

  34.2.3 in competition with the Restricted Business solicit, interfere with or entice away or endeavour to solicit, interfere with or entice away any Prospective Customer;

 

  34.2.4 in competition with the Restricted Business have business dealings with any Customer;

 

  34.2.5 in competition with the Restricted Business have business dealings with any Prospective Customer;

 

  34.2.6 solicit or induce or endeavour to solicit or induce any Relevant Person to cease working for or providing services to the Company, whether or not any such person would thereby commit a breach of contract;

 

  34.2.7 employ or otherwise engage in any business in competition with the Restricted Business any Relevant Person;

 

  34.2.8 encourage or cause or endeavour to encourage or cause any Supplier to cease providing goods and/or services to the Company or any Associated Employer;

 

  34.2.9 encourage or cause or endeavour to encourage or cause any Supplier to materially alter the terms of its business with the Company or any Associated Employer; and/or

 

21


  34.2.10 use or permit to be used any trade or service name or get-up used in the Company and/or any Associated Employer or any other name likely to be confused with such name and/or get-up.

 

34.3 While the restrictions in this clause 34 (on which you have had the opportunity to take independent legal advice, as you hereby acknowledge) are considered by the parties to be reasonable in all the circumstances, it is agreed that if any such restriction (including the definitions contained in clause 34.1), by itself, or taken together with the others, is found to be void but would be valid if some part of it were deleted, such restriction shall apply with such modification as may be necessary to make it valid and effective.

 

34.4 The parties agree that the restrictions set out in this clause 34 shall be separate and severable and enforceable as such. If any restriction is determined as being unenforceable in whole or in part for any reason, that shall not affect the enforceability of the remaining restrictions or, in the case of part of a restriction being unenforceable, the remainder of that restriction.

 

34.5 You hereby agree and undertake that you will upon receipt of any request from the Company to do so, enter into equivalent restrictions to those contained within this clause 34 directly with any Associated Employer with which you may be involved from time to time.

 

34.6 The Company may by notice to you at any time reduce in whole or in part the scope and/or duration of any of the restrictions set out in this agreement to such extent as the Company may in its sole and absolute discretion determine and thereupon such restrictions shall apply as modified by such notice.

 

34.7 The benefit of each restriction set out in this agreement shall be enforceable by the Company and any Associated Employer.

 

34.8 You undertake immediately to draw these restrictions to the attention of any person for or with whom you commence employment or work at any time during the period to which each restriction applies. For this purpose, the phrase “commences employment or work” includes entering into discussions or negotiations that are likely or intended to result in such commencement.

 

35. DATA PROTECTION

 

35.1 You consent to the Company or any Associated Employer holding and processing personal data as defined in the Data Protection Act 1998 (the “DPA”) concerning you in order to properly fulfil its obligations to you under this agreement and as otherwise required or permitted by law in relation to your employment in accordance with the DPA. Such processing shall principally be for legal, personnel, administrative and payroll purposes.

 

35.2 You accept and acknowledge that, if required at any time to work on behalf of the Company or any Associated Employer overseas, the Company may need to pass personal data concerning you to the person, firm or company with whom you are working anywhere in the world and you hereby expressly consent to the Company doing so.

 

35.3 You further consent to the Company and any Associated Employer processing any sensitive personal data (as defined in the DPA) relating to you, including, as appropriate:

 

22


  35.3.1 information about your physical or mental health or condition in order to monitor sick leave and take decisions as to fitness for work (including any medical report made by a medical practitioner nominated by the Company pursuant to clause 21);

 

  35.3.2 your racial or ethnic origin or religious or similar information in order to monitor compliance with equal opportunities legislation; and

 

  35.3.3 information relating to any criminal proceedings in which you may have been involved for insurance purposes and in order to comply with legal requirements and obligations to third parties.

 

35.4 You acknowledge that the Company and any Associated Employer may make any information to which clause 35 relates available to individuals or companies who provide products or services to the Company (such as advisers and payroll administrators), regulatory authorities, potential or future employers, governmental or quasi-governmental organisations and potential purchasers of the Company or the business in which you are employed.

 

36. MISREPRESENTATION

You must not at any time make any untrue statement in relation to the Company and, in particular, must not after the termination or expiration of the employment represent to any person that you remain employed by or connected with the Company.

 

37. PROVISIONS OPERATING AFTER TERMINATION OR EXPIRATION

 

37.1 The termination or expiration of the employment will not affect any provision of this agreement that operates or has effect or is expressed to operate or have effect after termination or expiration whether the employment is terminated or expires lawfully and fairly or otherwise.

 

37.2 No changes to this agreement will be effective unless made in writing and signed by the parties or on their behalf by any properly authorised person.

 

38. INVALIDITY OR UNENFORCEABILITY

The parties agree that each of the clauses and sub-clauses of this agreement shall be separate and severable and enforceable as such. The complete or partial invalidity or unenforceability of any provision of this agreement for any purpose will in no way affect the validity or enforceability of such provision for any other purpose or of the remaining provisions of this agreement.

 

23


39. SUPPLEMENTAL TERMS

 

39.1 Each Associated Employer and any of their agents may enforce the terms of this agreement directly against you pursuant to the Contracts (Rights of Third Parties) Act 1999.

 

39.2 Save as provided in clause 39.1 above, no term of this agreement shall be enforceable by any person who is not a party to it either under the Contracts (Rights of Third Parties) Act 1999 or otherwise.

 

39.3 There is no current requirement for you to work outside the United Kingdom for any consecutive period in excess of one month.

 

40. CHOICE OF LAW AND SUBMISSION TO JURISDICTION

This agreement will be governed by and construed in accordance with English law. The parties agree to submit to the exclusive jurisdiction of the English courts in relation to any claim or matter arising under this agreement.

IN WITNESS whereof this agreement has been executed as a deed by the parties on the date stated above.

 

EXECUTED AS A DEED by

 

acting by two directors or a director

and the company secretary

 

/s/ Frank Condella          sign here

Director

 

/s/ Jonathan Lloyd Jones          sign here

Director / Company Secretary

  

EXECUTED AS A DEED by

 

/s/Nikin Patel          sign here

in the presence of

 

/s/ Tom Brown        

Witness sign here

 

Tom Brown

Witness print name

 

Freeth Cartwright LLP

6 Bennetts Hill

Birmingham B2 55T

Witness address

 

24

Exhibit 99.1

 

LOGO

  Contact:   
 

Jonathan Lloyd Jones

   Seth Lewis
 

Vice President & CFO

   Senior Vice President
 

Columbia Laboratories, Inc.

   The Trout Group LLC
 

(617) 639-1500

   (646) 378-2952
    
  FOR IMMEDIATE RELEASE   

Columbia Laboratories Expands Board of Directors

Dr. Frank Armstrong and Dr. Nikin Patel Appointed Directors of the Company and

Dr. Martyn Davies Appointed Advisor to its Board of Directors

BOSTON, MA – September 16, 2013 – Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that its Board of Directors has appointed three experienced healthcare executives with over 65 years collective industry experience to its Board of Directors, effective immediately. Dr. Frank Armstrong and Dr. Nikin Patel have been appointed Directors of the Company, and Dr. Martyn Davies will serve as an Advisor to the Company’s Board. Drs. Davies and Patel are co-founders of Molecular Profiles Ltd. (“Molecular Profiles”).

Steve Kasnet, Chairman of Columbia’s Board of Directors, said, “We are pleased to welcome Drs. Armstrong, Patel and Davies to our Board of Directors. We look forward to benefiting from the insight and vast industry experience these knowledgeable individuals will bring.”

Dr. Frank Armstrong has over 20 years of experience in development and management at major pharmaceutical and leading biotechnology companies, spanning all aspects of the drug evaluation, development and commercialization processes. Dr. Armstrong led Medical Science and Innovation in R&D at Merck Serono and previously led Worldwide Product Development at Bayer AG and the Worldwide Medical Organization at Zeneca. He also served as CEO of Fulcrum Pharma plc and President and CEO of CuraGen Corp., among others.

Dr. Armstrong holds an honours degree and MBChB in Biochemistry and Medicine 1 from the University of Edinburgh in Scotland. He was elected as a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) in 1994, and Fellow of Royal College of Physicians, Edinburgh (FRCPE) in 1993. He currently serves on the Boards of six healthcare companies: Summit plc (non-executive Chairman), Asceneuron SA (executive Chairman), Xceleron (Chairman), Actino Pharma, Entelos and CardioRentis (non-executive Director).

Dr. Nikin Patel is the founding Chief Executive Officer of Molecular Profiles. Dr. Patel has over 15 years’ technical experience centered on pharmaceutical analysis and formulation development. His leadership was recognized externally through the U.K.’s most prestigious industry accolade, the Queen’s Award for Enterprise, won by Molecular Profiles both in 2007 and 2011 in the Innovation category.

Dr. Patel holds a first class honours degree and Ph.D. in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS). In addition to Columbia Laboratories, he is currently a director of Regentec Ltd, a regenerative medicine company.

Dr. Martyn Davies has over 30 years’ experience in the pharmaceutical, biopharmaceutical and drug delivery fields. He co-founded Molecular Profiles in 1997 as a spin-out company from his academic laboratory, and served as the company’s Founder-Chairman until its acquisition by Columbia Laboratories in September 2013. He played a key role in Molecular Profiles’ strategic development and also in leading and consulting on many technical projects for clients. Dr. Davies is also a Professor at the University of Nottingham’s School of Pharmacy.

 

1   The MBChB is awarded as M.D. in the United States.

 

4 Liberty Square • Fourth Floor • Boston, MA 02109

TEL: (617) 639-1500 • FAX: (617) 482-0618 • http://www.columbialabs.com


Columbia Laboratories Expands Board of Directors   
September 16, 2013    Page 2    

Dr. Davies holds a first class honours degree in Pharmacy from Brighton Polytechnic and a Ph.D. from King’s College, University of London. He has authored or co-authored more than 370 articles, is a Fellow of the Royal Society for Chemistry (FRSC) and Royal Pharmaceutical Society of Great Britain (FRPharmS), and is a past President of the Controlled Release Society (2011-12).

About Columbia Laboratories

Columbia Laboratories, Inc. is a profitable company with a rich heritage in drug development. The Company’s revenue streams include sales and royalty revenues from CRINONE ® 8% (progesterone gel), which is marketed by Actavis, Inc. in the United States and by Merck Serono S.A. in over 60 foreign countries, and revenues from its wholly-owned subsidiary Molecular Profiles Ltd., a U.K.-based provider of pharmaceutical formulation development and manufacturing services. For more information, please visit www.columbialabs.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words “may,” “will,” “plans,” “believes,” “expects,” “intends,” “anticipates,” “potential,” “should,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ from the forward-looking statements include, but are not limited to, the following: the successful transfer of quality management and technical support for CRINONE manufacturing activities to Molecular Profiles; Molecular Profiles’ ongoing ability to retain current and attract new customers; Columbia’s ability to realize the expected level of savings from operational synergies related to the acquisition of Molecular Profiles; the effect of converting Molecular Profiles’ financial statements from U.K. to U.S. GAAP; Actavis’ and Merck Serono’s success in marketing CRINONE for use in infertility in their respective markets; difficulties or delays in manufacturing; the availability and pricing of third-party sourced products and materials; successful compliance with FDA, MHRA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in laws and regulations; the ability to obtain and enforce patents and other intellectual property rights; the impact of competitive products and pricing; the cost of evaluating potential strategic transactions; the strength of the United States dollar relative to international currencies, particularly the British pound and euro; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia’s reports filed with the SEC including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2012. Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein.

CRINONE ® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S. Molecular Profiles™ is a registered trademark of Molecular Profiles Ltd.

###

 

4 Liberty Square • Fourth Floor • Boston, MA 02109

TEL: (617) 639-1500 • FAX: (617) 482-0618 • http://www.columbialabs.com